Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 464 articles:
HTML format
Text format



Single Articles


    March 2017
  1. MEROLA A, Romagnolo A, Comi C, Rosso M, et al
    Prevalence and burden of dysautonomia in advanced Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26970.
    PubMed     Text format    


  2. F HERNANDEZ L, Castela I, Ruiz-DeDiego I, Obeso JA, et al
    Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26947.
    PubMed     Text format     Abstract available


  3. ANDERKOVA L, Barton M, Rektorova I
    Striato-cortical connections in Parkinson's and Alzheimer's diseases: Relation to cognition.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26956.
    PubMed     Text format     Abstract available


  4. PAGANO G, Niccolini F, Yousaf T, Wilson H, et al
    Urinary dysfunction in early de novo patients with Parkinson's disease.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26967.
    PubMed     Text format    


  5. PEREZ XA, Zhang D, Bordia T, Quik M, et al
    Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26955.
    PubMed     Text format     Abstract available


  6. HANSEN AK, Damholdt MF, Fedorova TD, Knudsen K, et al
    In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.
    Mov Disord. 2017 Mar 3. doi: 10.1002/mds.26961.
    PubMed     Text format     Abstract available


  7. GIANNOCCARO MP, La Morgia C, Rizzo G, Carelli V, et al
    Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.
    Mov Disord. 2017 Mar 2. doi: 10.1002/mds.26966.
    PubMed     Text format     Abstract available


  8. MARRAS C
    What Would Dr. James Parkinson Think Today III: Measuring Health-Related Quality of Life.
    Mov Disord. 2017;32:364-365.
    PubMed     Text format    


    February 2017
  9. ESPAY AJ, Schwarzschild MA, Tanner CM, Fernandez HH, et al
    Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
    Mov Disord. 2017 Feb 24. doi: 10.1002/mds.26913.
    PubMed     Text format     Abstract available


  10. HORVATH K, Aschermann Z, Kovacs M, Makkos A, et al
    Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale.
    Mov Disord. 2017 Feb 20. doi: 10.1002/mds.26960.
    PubMed     Text format     Abstract available


  11. MIKI Y, Yoshizawa T, Morohashi S, Seino Y, et al
    Neuropathology of PARK14 is identical to idiopathic Parkinson's disease.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26952.
    PubMed     Text format    


  12. ROSA M, Arlotti M, Marceglia S, Cogiamanian F, et al
    Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients.
    Mov Disord. 2017 Feb 17. doi: 10.1002/mds.26953.
    PubMed     Text format    


  13. HILL-BURNS EM, Debelius JW, Morton JT, Wissemann WT, et al
    Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Mov Disord. 2017 Feb 14. doi: 10.1002/mds.26942.
    PubMed     Text format     Abstract available


  14. PONZO V, Di Lorenzo F, Brusa L, Schirinzi T, et al
    Impaired intracortical transmission in G2019S leucine rich-repeat kinase Parkinson patients.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26931.
    PubMed     Text format     Abstract available


  15. ANSARI M, Sobhani S
    Impaired glutamate release in GPe astrocytes, disinhibits striatopallidal transmission in Parkinsonian mice.
    Mov Disord. 2017 Feb 10. doi: 10.1002/mds.26943.
    PubMed     Text format    


  16. GALLEA C, Ewenczyk C, Degos B, Welter ML, et al
    Pedunculopontine network dysfunction in Parkinson's disease with postural control and sleep disorders.
    Mov Disord. 2017 Feb 6. doi: 10.1002/mds.26923.
    PubMed     Text format     Abstract available


  17. DEL REY NL, Blesa J
    Parkinson's disease: Oh my gut!
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26933.
    PubMed     Text format    


  18. MAHLKNECHT P, Krismer F, Poewe W, Seppi K, et al
    Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26932.
    PubMed     Text format     Abstract available


  19. MOLLER L, Kassubek J, Sudmeyer M, Hilker R, et al
    Manual MRI morphometry in Parkinsonian syndromes.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26921.
    PubMed     Text format     Abstract available


  20. STRAFELLA AP, Bohnen NI, Perlmutter JS, Eidelberg D, et al
    Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers.
    Mov Disord. 2017 Feb 2. doi: 10.1002/mds.26907.
    PubMed     Text format     Abstract available


  21. OLANOW CW, Kordower JH
    Targeting alpha-Synuclein as a therapy for Parkinson's disease: The battle begins.
    Mov Disord. 2017;32:203-207.
    PubMed     Text format    


  22. ALBIN RL
    What would Dr. James Parkinson think today? II. Neuroimaging in Parkinson's disease.
    Mov Disord. 2017;32:179-180.
    PubMed     Text format    


  23. EBRAHIMI R, Sobhani S, Abbastabar M
    Whether the dissociation between toxicity and alpha-synuclein inclusion will be a possible therapy for Parkinson's disease or not?
    Mov Disord. 2017;32:210.
    PubMed     Text format    



  24. Abstracts of the 1st Pan American Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2017;32 Suppl 1:S1-S90.
    PubMed     Text format    


    January 2017
  25. MORBERG BM, Malling AS, Jensen BR, Gredal O, et al
    Parkinson's disease and transcranial pulsed electromagnetic fields: A randomized clinical trial.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26927.
    PubMed     Text format    


  26. VIDENOVIC A
    Management of sleep disorders in Parkinson's disease and multiple system atrophy.
    Mov Disord. 2017 Jan 24. doi: 10.1002/mds.26918.
    PubMed     Text format     Abstract available


  27. NOYCE AJ, R'Bibo L, Peress L, Bestwick JP, et al
    PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26898.
    PubMed     Text format     Abstract available


  28. QUADRI M, Breedveld GJ, Chang HC, Yeh TH, et al
    Mutations in TMEM230 are not a common cause of Parkinson's disease.
    Mov Disord. 2017 Jan 16. doi: 10.1002/mds.26900.
    PubMed     Text format    


  29. MOHASEL S, Sobhani S
    The role of amyloidogenic proteins as a meeting point of type 2 diabetes and Parkinson's disease pathways.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26897.
    PubMed     Text format    


  30. VISANJI NP, Bhudhikanok GS, Mestre TA, Ghate T, et al
    Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26896.
    PubMed     Text format     Abstract available


  31. SCHNEIDER SA, Bras J
    Mouse models of kufor-rakeb disease link Parkinson's disease closer to neuronal ceroid lipofuscinosis, suggesting lysosomal dysfunction as shared mechanism.
    Mov Disord. 2017 Jan 10. doi: 10.1002/mds.26899.
    PubMed     Text format    


  32. BESTE C, Muckschel M, Rosales R, Domingo A, et al
    Striosomal dysfunction affects behavioral adaptation but not impulsivity-Evidence from X-linked dystonia-parkinsonism.
    Mov Disord. 2017 Jan 6. doi: 10.1002/mds.26895.
    PubMed     Text format     Abstract available


  33. SPATARO N, Roca-Umbert A, Cervera-Carles L, Valles M, et al
    Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients.
    Mov Disord. 2017;32:165-169.
    PubMed     Text format     Abstract available


  34. ZHANG M, Xi Z, Misquitta K, Sato C, et al
    C9orf72 and ATXN2 repeat expansions coexist in a family with ataxia, dementia, and parkinsonism.
    Mov Disord. 2017;32:158-162.
    PubMed     Text format     Abstract available


  35. HARIZ M, Obeso JA
    What Would Dr. James Parkinson Think Today? I. The Role of Functional Neurosurgery for Parkinson's Disease.
    Mov Disord. 2017;32:2-4.
    PubMed     Text format    


    December 2016
  36. LANGLEY J, Huddleston DE, Sedlacik J, Boelmans K, et al
    Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26883.
    PubMed     Text format     Abstract available


  37. RAHMANI F, Kamalian A, Aarabi MH
    New evidence comes to light: How is alpha-synuclein aggregation related to mitochondrial protein import in Parkinson's disease?
    Mov Disord. 2016 Dec 22. doi: 10.1002/mds.26889.
    PubMed     Text format    


  38. BLAUWENDRAAT C, Nalls MA, Federoff M, Pletnikova O, et al
    ADORA1 mutations are not a common cause of Parkinson's disease and dementia with Lewy bodies.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26886.
    PubMed     Text format    


  39. SENEK M, Nielsen EI, Nyholm D
    Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.
    Mov Disord. 2016 Dec 17. doi: 10.1002/mds.26855.
    PubMed     Text format     Abstract available


  40. PAL GD, Ouyang B, Serrano G, Shill HA, et al
    Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26882.
    PubMed     Text format     Abstract available


  41. DZAMKO N, Gysbers AM, Bandopadhyay R, Bolliger MF, et al
    LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26892.
    PubMed     Text format     Abstract available


  42. MARTINEZ-MARTIN P
    What is quality of life and how do we measure it? Relevance to Parkinson's disease and movement disorders.
    Mov Disord. 2016 Dec 2. doi: 10.1002/mds.26885.
    PubMed     Text format     Abstract available


  43. GOETZ CG, Liu Y, Stebbins GT, Wang L, et al
    Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Mov Disord. 2016;31:1865-1873.
    PubMed     Text format     Abstract available


  44. WILLIS AW, Thibault DP, Schmidt PN, Dorsey ER, et al
    Hospital care for mental health and substance abuse conditions in Parkinson's disease.
    Mov Disord. 2016;31:1810-1819.
    PubMed     Text format     Abstract available


  45. SHI CH, Zhang SY, Yang ZH, Yang J, et al
    A novel RAB39B gene mutation in X-linked juvenile parkinsonism with basal ganglia calcification.
    Mov Disord. 2016;31:1905-1909.
    PubMed     Text format     Abstract available


    November 2016
  46. DE PABLO-FERNANDEZ E, Courtney R, Holton JL, Warner TT, et al
    Hypothalamic alpha-synuclein and its relation to weight loss and autonomic symptoms in Parkinson's disease.
    Mov Disord. 2016 Nov 28. doi: 10.1002/mds.26868.
    PubMed     Text format    


  47. KNUDSEN K, Krogh K, Ostergaard K, Borghammer P, et al
    Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26866.
    PubMed     Text format     Abstract available


  48. PILLAS M, Selai C, Schrag A
    Rasch analysis of the carers quality of life questionnaire for parkinsonism.
    Mov Disord. 2016 Nov 22. doi: 10.1002/mds.26877.
    PubMed     Text format     Abstract available


  49. RAUSCHENDORF MA, Jost M, Stock F, Zimmer A, et al
    Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26876.
    PubMed     Text format    


  50. HE YC, Huang P, Li QQ, Sun Q, et al
    TMEM230 stop codon mutation is rare in parkinson's disease and essential tremor in eastern China.
    Mov Disord. 2016 Nov 21. doi: 10.1002/mds.26875.
    PubMed     Text format    


  51. POLITIS M, Sauerbier A, Loane C, Pavese N, et al
    Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.
    Mov Disord. 2016 Nov 17. doi: 10.1002/mds.26848.
    PubMed     Text format     Abstract available


  52. GALIMBERTI D, Cioffi SM, Fenoglio C, Serpente M, et al
    Rapidly progressive primary progressive aphasia and parkinsonism with novel GRN mutation.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26872.
    PubMed     Text format    


  53. FIFEL K
    Alterations of the circadian system in Parkinson's disease patients.
    Mov Disord. 2016 Nov 15. doi: 10.1002/mds.26865.
    PubMed     Text format     Abstract available


  54. ISOTALO J, Vahlberg T, Kaasinen V
    Unchanged long-term rural-to-urban incidence ratio of Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26862.
    PubMed     Text format    


  55. XIE T, Kang UJ
    Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26861.
    PubMed     Text format    


  56. GAARE JJ, Skeie GO, Tzoulis C, Larsen JP, et al
    Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26856.
    PubMed     Text format     Abstract available


  57. PINTO DE SOUZA C, Hamani C, Oliveira Souza C, Lopez Contreras WO, et al
    Spinal cord stimulation improves gait in patients with Parkinson's disease previously treated with deep brain stimulation.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26850.
    PubMed     Text format     Abstract available


  58. KLETTNER A, Tholey A, Wiegandt A, Richert E, et al
    Reduction of GAPDH in lenses of Parkinson's disease patients: A possible new biomarker.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26863.
    PubMed     Text format     Abstract available


  59. BEUDEL M, Oswal A, Jha A, Foltynie T, et al
    Oscillatory Beta Power Correlates With Akinesia-Rigidity in the Parkinsonian Subthalamic Nucleus.
    Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26860.
    PubMed     Text format    


  60. DI BIASE L, Fasano A
    Reply to: Comments on recent viewpoint article by Lazzaro di Biase and Alfonso Fasano titled "Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?"
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26859.
    PubMed     Text format    


  61. NEUMANN WJ, Kuhn AA
    Subthalamic beta power-Unified Parkinson's disease rating scale III correlations require akinetic symptoms.
    Mov Disord. 2016 Nov 9. doi: 10.1002/mds.26858.
    PubMed     Text format    


  62. SGAMBATO-FAURE V
    Control of the direct pathway by cholinergic interneurons is involved in parkinsonian motor symptoms.
    Mov Disord. 2016 Nov 2. doi: 10.1002/mds.26840.
    PubMed     Text format    


    October 2016
  63. FOO JN, Lee J, Tan LC, Liu J, et al
    Large 3-Mb deletions at 22q11.2 locus in parkinson's disease and schizophrenia.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26822.
    PubMed     Text format    


  64. HUGHES KC, Gao X, Kim IY, Rimm EB, et al
    Intake of antioxidant vitamins and risk of parkinson's disease.
    Mov Disord. 2016 Oct 27. doi: 10.1002/mds.26819.
    PubMed     Text format     Abstract available


  65. TINAZZI M, Geroin C, Gandolfi M, Smania N, et al
    Pisa syndrome in Parkinson's disease: An integrated approach from pathophysiology to management.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26829.
    PubMed     Text format     Abstract available


  66. MANGESIUS S, Krismer F, Gizewski ER, Muller C, et al
    1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26823.
    PubMed     Text format    


  67. SAVICA R, Grossardt BR, Bower JH, Ahlskog JE, et al
    Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
    Mov Disord. 2016 Oct 25. doi: 10.1002/mds.26839.
    PubMed     Text format     Abstract available


  68. TARSY D
    Addition of a virtual reality component to treadmill training to reduce fall risk in older adults, including individuals with Parkinson's disease.
    Mov Disord. 2016 Oct 19. doi: 10.1002/mds.26843.
    PubMed     Text format    


  69. KHODADADI H, Azcona LJ, Aghamollaii V, Omrani MD, et al
    PTRHD1 (C2orf79) mutations lead to autosomal-recessive intellectual disability and parkinsonism.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26824.
    PubMed     Text format     Abstract available


  70. TROSTER AI, Jankovic J, Tagliati M, Peichel D, et al
    Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26827.
    PubMed     Text format     Abstract available


  71. PYLE A, Lowes H, Brennan R, Kurzawa-Akanbi M, et al
    Reduced mitochondrial DNA is not a biomarker of depression in Parkinson's disease.
    Mov Disord. 2016 Oct 18. doi: 10.1002/mds.26825.
    PubMed     Text format    


  72. BALINT B, Bhatia KP
    SLC39A14 mutations expand the spectrum of manganese transporter defects causing parkinsonism-dystonia.
    Mov Disord. 2016 Oct 14. doi: 10.1002/mds.26821.
    PubMed     Text format    


  73. KLEIN C, Lochte T, Delamonte SM, Braenne I, et al
    PLA2G6 mutations and Parkinsonism: Long-term follow-up of clinical Features and Neuropathology.
    Mov Disord. 2016 Oct 6. doi: 10.1002/mds.26814.
    PubMed     Text format    


  74. POLLI A, Weis L, Biundo R, Thacker M, et al
    Anatomical and functional correlates of persistent pain in parkinson's disease.
    Mov Disord. 2016 Oct 5. doi: 10.1002/mds.26826.
    PubMed     Text format     Abstract available


    September 2016
  75. PONS R, Kekou K, Antonellou R, Svingou M, et al
    Analysis of a founder mutation in the TH gene in a cohort of greek patients with Parkinson's disease.
    Mov Disord. 2016 Sep 26. doi: 10.1002/mds.26807.
    PubMed     Text format    


  76. SVENSSON E, Horvath-Puho E, Stokholm MG, Sorensen HT, et al
    Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26761.
    PubMed     Text format     Abstract available


  77. LORD S, Galna B, Yarnall AJ, Coleman S, et al
    Predicting first fall in newly diagnosed Parkinson's disease: Insights from a fall-naive cohort.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26742.
    PubMed     Text format     Abstract available


  78. WONG YC, Krainc D
    Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26802.
    PubMed     Text format     Abstract available


  79. KETT LR, Dauer WT
    Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26797.
    PubMed     Text format     Abstract available


  80. RIEDEL O
    Bringing light into the darkness: Dependence in Parkinson's disease.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26795.
    PubMed     Text format    


  81. DELVAL A, Rambour M, Tard C, Dujardin K, et al
    Freezing/festination during motor tasks in early-stage Parkinson's disease: A prospective study.
    Mov Disord. 2016 Sep 13. doi: 10.1002/mds.26762.
    PubMed     Text format     Abstract available


    August 2016
  82. KIM JM, Jang ES, Ok K, Oh ES, et al
    Association between hepatitis C virus infection and Parkinson's disease.
    Mov Disord. 2016 Aug 23. doi: 10.1002/mds.26755.
    PubMed     Text format    


  83. MAJBOUR NK, Vaikath NN, Eusebi P, Chiasserini D, et al
    Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26754.
    PubMed     Text format     Abstract available


  84. ONDER H
    Dominant-side onset in Parkinson's disease and better motor performance?
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26752.
    PubMed     Text format    


  85. MACLEOD AD, Counsell CE
    Predictors of functional dependency in Parkinson's disease.
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26751.
    PubMed     Text format     Abstract available


  86. SOHN YH, Ham JH
    Dominant-side onset in Parkinson's disease and better motor performance?
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26750.
    PubMed     Text format    


  87. NEUMANN WJ, Degen K, Schneider GH, Brucke C, et al
    Subthalamic synchronized oscillatory activity correlates with motor impairment in patients with Parkinson's disease.
    Mov Disord. 2016 Aug 22. doi: 10.1002/mds.26759.
    PubMed     Text format     Abstract available


  88. FIGGE DA, Standaert DG
    SNPing SCNA regulatory elements gives a CRISPR view of genetic susceptibility in Parkinson's disease.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26747.
    PubMed     Text format    


  89. DORSEY ER, Vlaanderen FP, Engelen LJ, Kieburtz K, et al
    Moving Parkinson care to the home.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26744.
    PubMed     Text format     Abstract available


  90. VARANDA S, Ribeiro da Silva J, Costa AS, Amorim de Carvalho C, et al
    Sexual dysfunction in women with Parkinson's disease.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26739.
    PubMed     Text format     Abstract available


  91. KUBOTA KJ, Chen JA, Little MA
    Machine learning for large-scale wearable sensor data in Parkinson's disease: Concepts, promises, pitfalls, and futures.
    Mov Disord. 2016 Aug 8. doi: 10.1002/mds.26693.
    PubMed     Text format     Abstract available


  92. SANCHEZ-FERRO A, Maetzler W
    Advances in sensor and wearable technologies for Parkinson's disease.
    Mov Disord. 2016 Aug 1. doi: 10.1002/mds.26746.
    PubMed     Text format    


  93. PIFL C
    Problems with traffic ahead: Synaptic vesicles in Parkinson's disease.
    Mov Disord. 2016 Aug 1. doi: 10.1002/mds.26735.
    PubMed     Text format    


  94. LAHUE SC, Comella CL, Tanner CM
    The best medicine? The influence of physical activity and inactivity on Parkinson's disease.
    Mov Disord. 2016 Aug 1. doi: 10.1002/mds.26728.
    PubMed     Text format     Abstract available


  95. DAMS J, Balzer-Geldsetzer M, Siebert U, Deuschl G, et al
    Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
    Mov Disord. 2016;31:1183-91.
    PubMed     Text format     Abstract available


    July 2016
  96. KRISMER F, Seppi K, Wenning GK, Abler V, et al
    Minimally clinically important decline in the parkinsonian variant of multiple system atrophy.
    Mov Disord. 2016 Jul 30. doi: 10.1002/mds.26743.
    PubMed     Text format     Abstract available


  97. WESSEL JR, Ghahremani A, Udupa K, Saha U, et al
    Stop-related subthalamic beta activity indexes global motor suppression in Parkinson's disease.
    Mov Disord. 2016 Jul 30. doi: 10.1002/mds.26732.
    PubMed     Text format     Abstract available


  98. BERMAN BD, Smucny J, Wylie KP, Shelton E, et al
    Levodopa modulates small-world architecture of functional brain networks in Parkinson's disease.
    Mov Disord. 2016 Jul 27. doi: 10.1002/mds.26713.
    PubMed     Text format     Abstract available


  99. DEL DIN S, Godfrey A, Mazza C, Lord S, et al
    Free-living monitoring of Parkinson's disease: Lessons from the field.
    Mov Disord. 2016 Jul 25. doi: 10.1002/mds.26718.
    PubMed     Text format     Abstract available


  100. HUPPERTZ HJ, Moller L, Sudmeyer M, Hilker R, et al
    Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification.
    Mov Disord. 2016 Jul 25. doi: 10.1002/mds.26715.
    PubMed     Text format     Abstract available


  101. SVENNINGSSON P, Wirdefeldt K, Yin L, Fang F, et al
    Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26734.
    PubMed     Text format    


  102. MARTINEZ-FERNANDEZ R, Schmitt E, Martinez-Martin P, Krack P, et al
    The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26731.
    PubMed     Text format     Abstract available


  103. RASCOL O, Hauser RA, Stocchi F, Fitzer-Attas CJ, et al
    Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26724.
    PubMed     Text format     Abstract available


  104. SANCHEZ-FERRO A, Elshehabi M, Godinho C, Salkovic D, et al
    New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26723.
    PubMed     Text format     Abstract available


  105. MIRELMAN A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, et al
    Arm swing as a potential new prodromal marker of Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26720.
    PubMed     Text format     Abstract available


  106. NONNEKES J, Timmer MH, de Vries NM, Rascol O, et al
    Unmasking levodopa resistance in Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26712.
    PubMed     Text format     Abstract available


  107. SANKAR T, Li SX, Obuchi T, Fasano A, et al
    Structural brain changes following subthalamic nucleus deep brain stimulation in Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26707.
    PubMed     Text format    


  108. HAUSER RA, Olanow CW, Dzyngel B, Bilbault T, et al
    Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
    Mov Disord. 2016 Jul 19. doi: 10.1002/mds.26697.
    PubMed     Text format     Abstract available


  109. LOEFFLER DA, LeWitt PA, Camp DM
    Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease?
    Mov Disord. 2016 Jul 14. doi: 10.1002/mds.26711.
    PubMed     Text format    


  110. MESTRE TA, Sidiropoulos C, Hamani C, Poon YY, et al
    Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease.
    Mov Disord. 2016 Jul 9. doi: 10.1002/mds.26710.
    PubMed     Text format     Abstract available



  111. Retraction: 'Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial,' by Sato, Y., Iwamoto, J., Kanoko, T., and Satoh, K.
    Mov Disord. 2016;31:1077.
    PubMed     Text format     Abstract available


    June 2016
  112. ANTUNES L, Frasquilho S, Ostaszewski M, Weber J, et al
    Similar alpha-Synuclein staining in the colon mucosa in patients with Parkinson's disease and controls.
    Mov Disord. 2016 Jun 21. doi: 10.1002/mds.26702.
    PubMed     Text format     Abstract available


  113. DAMS J, Dodel R
    An economic evaluation of deep brain stimulation for patients with Parkinson's disease.
    Mov Disord. 2016 Jun 21. doi: 10.1002/mds.26701.
    PubMed     Text format    


  114. MALEK N, Lawton MA, Swallow DM, Grosset KA, et al
    Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease.
    Mov Disord. 2016 Jun 21. doi: 10.1002/mds.26698.
    PubMed     Text format     Abstract available


  115. FRASER KB, Rawlins AB, Clark RG, Alcalay RN, et al
    Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.
    Mov Disord. 2016 Jun 14. doi: 10.1002/mds.26686.
    PubMed     Text format     Abstract available


  116. ROSSI M, Escobar AM, Bril A, Millar Vernetti P, et al
    Motor features in Parkinson's disease with normal olfactory function.
    Mov Disord. 2016 Jun 9. doi: 10.1002/mds.26687.
    PubMed     Text format     Abstract available


  117. MAETZLER W, Klucken J, Horne M
    A clinical view on the development of technology-based tools in managing Parkinson's disease.
    Mov Disord. 2016 Jun 7. doi: 10.1002/mds.26673.
    PubMed     Text format     Abstract available


  118. MAHLKNECHT P, Gasperi A, Willeit P, Kiechl S, et al
    Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community.
    Mov Disord. 2016 Jun 6. doi: 10.1002/mds.26674.
    PubMed     Text format     Abstract available


  119. COTELLI M, Manenti R, Brambilla M, Borroni B, et al
    Reply to letter to the editor "tDCS effect on cognitive performance in Parkinson's disease" by Biundo et al.
    Mov Disord. 2016 Jun 6. doi: 10.1002/mds.26684.
    PubMed     Text format    


  120. NAKAMURA T, Suzuki M, Okada A, Suzuki J, et al
    Association of leptin with orthostatic blood pressure changes in Parkinson's disease.
    Mov Disord. 2016 Jun 6. doi: 10.1002/mds.26678.
    PubMed     Text format     Abstract available


  121. BIUNDO R, Weis L, Antonini A
    tDCS effect on cognitive performance in Parkinson's disease.
    Mov Disord. 2016 Jun 2. doi: 10.1002/mds.26685.
    PubMed     Text format    


  122. CALABRESI P, Standaert DG, Chiasserini D, Parnetti L, et al
    Biomarkers in Parkinson's disease: From pathophysiology to early diagnosis.
    Mov Disord. 2016;31:769-70.
    PubMed     Text format    



  123. Abstracts of the Twentieth International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2016;31 Suppl 2:S1-S802.
    PubMed     Text format    


    May 2016
  124. VAN UEM JM, Maier KS, Hucker S, Scheck O, et al
    Twelve-week sensor assessment in Parkinson's disease: Impact on quality of life.
    Mov Disord. 2016 May 31. doi: 10.1002/mds.26676.
    PubMed     Text format    


  125. MARRAS C, Lang AE, Austin PC, Lau C, et al
    Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study.
    Mov Disord. 2016 May 31. doi: 10.1002/mds.26670.
    PubMed     Text format     Abstract available


  126. NUTT JG
    Motor subtype in Parkinson's disease: Different disorders or different stages of disease?
    Mov Disord. 2016 May 26. doi: 10.1002/mds.26657.
    PubMed     Text format    


  127. VENUTO CS, Potter NB, Ray Dorsey E, Kieburtz K, et al
    A review of disease progression models of Parkinson's disease and applications in clinical trials.
    Mov Disord. 2016 May 26. doi: 10.1002/mds.26644.
    PubMed     Text format     Abstract available


  128. HIRSCHMANN J, Butz M, Hartmann CJ, Hoogenboom N, et al
    Parkinsonian Rest Tremor Is Associated With Modulations of Subthalamic High-Frequency Oscillations.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26663.
    PubMed     Text format     Abstract available


  129. TISON F, Keywood C, Wakefield M, Durif F, et al
    A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26659.
    PubMed     Text format     Abstract available


  130. TRENKWALDER C, Stocchi F, Poewe W, Dronamraju N, et al
    Mavoglurant in Parkinson's Patients With l-Dopa-Induced Dyskinesias: Two Randomized Phase 2 Studies.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26585.
    PubMed     Text format     Abstract available


  131. SCHREGLMANN SR, Houlden H
    VPS13C-Another Hint at Mitochondrial Dysfunction in Familial Parkinson's Disease.
    Mov Disord. 2016 May 23. doi: 10.1002/mds.26682.
    PubMed     Text format    


  132. DELGADO-ALVARADO M, Gago B, Navalpotro-Gomez I, Jimenez-Urbieta H, et al
    Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.
    Mov Disord. 2016 May 19. doi: 10.1002/mds.26662.
    PubMed     Text format     Abstract available


  133. SHULMAN LM, Armstrong M, Ellis T, Gruber-Baldini A, et al
    Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.
    Mov Disord. 2016 May 19. doi: 10.1002/mds.26649.
    PubMed     Text format     Abstract available


  134. SCHIRINZI T, Madeo G, Martella G, Maltese M, et al
    Early synaptic dysfunction in Parkinson's disease: Insights from animal models.
    Mov Disord. 2016 May 19. doi: 10.1002/mds.26620.
    PubMed     Text format     Abstract available


  135. DI BIASE L, Fasano A
    Low-frequency deep brain stimulation for Parkinson's disease: Great expectation or false hope?
    Mov Disord. 2016 May 13. doi: 10.1002/mds.26658.
    PubMed     Text format     Abstract available


  136. MAHLKNECHT P, Pechlaner R, Boesveldt S, Volc D, et al
    Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease.
    Mov Disord. 2016 May 9. doi: 10.1002/mds.26637.
    PubMed     Text format     Abstract available


  137. BLENNOW K, Biscetti L, Eusebi P, Parnetti L, et al
    Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.
    Mov Disord. 2016 May 4. doi: 10.1002/mds.26656.
    PubMed     Text format     Abstract available


  138. TESSITORE A, Giordano A, De Micco R, Caiazzo G, et al
    Functional connectivity underpinnings of fatigue in "Drug-Naive" patients with Parkinson's disease.
    Mov Disord. 2016 May 4. doi: 10.1002/mds.26650.
    PubMed     Text format     Abstract available


  139. HALBGEBAUER S, Ockl P, Wirth K, Steinacker P, et al
    Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins.
    Mov Disord. 2016 May 2. doi: 10.1002/mds.26635.
    PubMed     Text format     Abstract available


  140. JABERI E, Rohani M, Shahidi GA, Nafissi S, et al
    Mutation in ADORA1 identified as likely cause of early-onset parkinsonism and cognitive dysfunction.
    Mov Disord. 2016 May 2. doi: 10.1002/mds.26627.
    PubMed     Text format     Abstract available


  141. YARNALL AJ, Lashley T, Ling H, Lees AJ, et al
    Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?
    Mov Disord. 2016;31:668-75.
    PubMed     Text format     Abstract available


    April 2016
  142. OLSZEWSKA DA, Lynch T
    MUL1-A new potential for a therapeutic target for Parkinson's disease a commentary on "MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin" by Yun and colleagues (eLife 2014; 3: 1-26).
    Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26652.
    PubMed     Text format    


  143. BROEN MP, Narayen NE, Kuijf ML, Dissanayaka NN, et al
    Prevalence of anxiety in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26643.
    PubMed     Text format     Abstract available


  144. ESPAY AJ, Bonato P, Nahab FB, Maetzler W, et al
    Technology in Parkinson's disease: Challenges and opportunities.
    Mov Disord. 2016 Apr 29. doi: 10.1002/mds.26642.
    PubMed     Text format     Abstract available


  145. KANG UJ, Goldman JG, Alcalay RN, Xie T, et al
    The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort.
    Mov Disord. 2016 Apr 26. doi: 10.1002/mds.26613.
    PubMed     Text format     Abstract available


  146. LOANE C, Politis M, Kefalopoulou Z, Valle-Guzman N, et al
    Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study.
    Mov Disord. 2016 Apr 22. doi: 10.1002/mds.26606.
    PubMed     Text format     Abstract available


  147. URIBE C, Segura B, Baggio HC, Abos A, et al
    Patterns of Cortical Thinning in Nondemented Parkinson's Disease Patients.
    Mov Disord. 2016 Apr 20. doi: 10.1002/mds.26590.
    PubMed     Text format     Abstract available


  148. ROSS GW, Petrovitch H, Abbott RD
    Serum vitamin D and risk of Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26639.
    PubMed     Text format    


  149. MCDONALD C, Newton JL, Burn DJ
    Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26632.
    PubMed     Text format     Abstract available


  150. ZHANG J, Nombela C, Wolpe N, Barker RA, et al
    Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26631.
    PubMed     Text format     Abstract available


  151. SCHAPIRA AH, Chiasserini D, Beccari T, Parnetti L, et al
    Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26616.
    PubMed     Text format     Abstract available


  152. MARRAS C, Alcalay RN, Caspell-Garcia C, Coffey C, et al
    Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26614.
    PubMed     Text format     Abstract available


  153. LEWITT PA, Hauser RA, Grosset DG, Stocchi F, et al
    A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26611.
    PubMed     Text format     Abstract available


  154. SHRESTHA S, Lutsey PL, Alonso A, Huang X, et al
    Serum 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk.
    Mov Disord. 2016 Apr 19. doi: 10.1002/mds.26573.
    PubMed     Text format     Abstract available


  155. CAVINESS JN, Lue LF, Hentz JG, Schmitz CT, et al
    Cortical phosphorylated alpha-Synuclein levels correlate with brain wave spectra in Parkinson's disease.
    Mov Disord. 2016 Apr 8. doi: 10.1002/mds.26621.
    PubMed     Text format     Abstract available


  156. MARRAS C, Lang A, van de Warrenburg BP, Sue CM, et al
    Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.
    Mov Disord. 2016;31:436-57.
    PubMed     Text format     Abstract available


  157. GREENE P
    Are more effective placebos complicating clinical trials?
    Mov Disord. 2016;31:606.
    PubMed     Text format    


  158. WEISS D, Herrmann S, Wang L, Schulte C, et al
    Alpha-synuclein gene variants may predict neurostimulation outcome.
    Mov Disord. 2016;31:601-3.
    PubMed     Text format    


  159. LAWTON M, Kasten M, May MT, Mollenhauer B, et al
    Validation of conversion between mini-mental state examination and montreal cognitive assessment.
    Mov Disord. 2016;31:593-6.
    PubMed     Text format     Abstract available


  160. LANG AE, Rodriguez RL, Boyd JT, Chouinard S, et al
    Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials.
    Mov Disord. 2016;31:538-46.
    PubMed     Text format     Abstract available


    March 2016
  161. FORLONI G, Artuso V, La Vitola P, Balducci C, et al
    Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases.
    Mov Disord. 2016 Mar 31. doi: 10.1002/mds.26624.
    PubMed     Text format     Abstract available


  162. WEINTRAUB D, Hauser RA, Elm JJ, Pagan F, et al
    Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
    Mov Disord. 2016 Mar 31. doi: 10.1002/mds.26617.
    PubMed     Text format     Abstract available


  163. ADLER CH, Beach TG
    Neuropathological basis of nonmotor manifestations of Parkinson's disease.
    Mov Disord. 2016 Mar 31. doi: 10.1002/mds.26605.
    PubMed     Text format     Abstract available


  164. COPELAND JN, Lieberman A, Oravivattanakul S, Troster AI, et al
    Accuracy of Patient and Care Partner Identification of Cognitive Impairments in Parkinson's Disease-Mild Cognitive Impairment.
    Mov Disord. 2016 Mar 29. doi: 10.1002/mds.26619.
    PubMed     Text format     Abstract available


  165. KLUGER BM, Rakowski D, Christian M, Cedar D, et al
    Randomized, Controlled Trial of Acupuncture for Fatigue in Parkinson's Disease.
    Mov Disord. 2016 Mar 29. doi: 10.1002/mds.26597.
    PubMed     Text format     Abstract available


  166. DE GERMAY S, Montastruc JL, Rousseau V, Chebane L, et al
    Atropinic (Anticholinergic) Burden in Parkinson's Disease.
    Mov Disord. 2016 Mar 29. doi: 10.1002/mds.26595.
    PubMed     Text format     Abstract available


  167. WILLIAMS-GRAY CH, Wijeyekoon R, Yarnall AJ, Lawson RA, et al
    Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
    Mov Disord. 2016 Mar 21. doi: 10.1002/mds.26563.
    PubMed     Text format     Abstract available


  168. FLORES-CUADRADO A, Ubeda-Banon I, Saiz-Sanchez D, de la Rosa-Prieto C, et al
    Hippocampal alpha-synuclein and interneurons in Parkinson's disease: Data from human and mouse models.
    Mov Disord. 2016 Mar 18. doi: 10.1002/mds.26586.
    PubMed     Text format     Abstract available


  169. BAE YJ, Kim JM, Kim E, Lee KM, et al
    Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With I-FP-CIT SPECT.
    Mov Disord. 2016 Mar 17. doi: 10.1002/mds.26584.
    PubMed     Text format     Abstract available


  170. QUADRI M, Olgiati S, Sensi M, Gualandi F, et al
    PRKRA Mutation Causing Early-Onset Generalized Dystonia-Parkinsonism (DYT16) in an Italian Family.
    Mov Disord. 2016 Mar 17. doi: 10.1002/mds.26583.
    PubMed     Text format    


  171. NACKAERTS E, Heremans E, Vervoort G, Smits-Engelsman BC, et al
    Relearning of Writing Skills in Parkinson's Disease After Intensive Amplitude Training.
    Mov Disord. 2016 Mar 17. doi: 10.1002/mds.26565.
    PubMed     Text format     Abstract available


  172. BREEN DP, Nombela C, Vuono R, Jones PS, et al
    Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease.
    Mov Disord. 2016 Mar 12. doi: 10.1002/mds.26592.
    PubMed     Text format     Abstract available


  173. TAN B, Double KL, Burne J, Diong J, et al
    Tension-referenced measures of gastrocnemius slack length and stiffness in Parkinson's disease.
    Mov Disord. 2016 Mar 11. doi: 10.1002/mds.26530.
    PubMed     Text format     Abstract available


  174. HERZ DM, Haagensen BN, Nielsen SH, Madsen KH, et al
    Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson's disease.
    Mov Disord. 2016 Mar 8. doi: 10.1002/mds.26540.
    PubMed     Text format     Abstract available


  175. VICENTE MIRANDA H, El-Agnaf OM, Outeiro TF
    Glycation in Parkinson's disease and Alzheimer's disease.
    Mov Disord. 2016 Mar 4. doi: 10.1002/mds.26566.
    PubMed     Text format     Abstract available


  176. RICCIARDI L, Bove F, Espay KJ, Lena F, et al
    24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Mov Disord. 2016 Mar 4. doi: 10.1002/mds.26564.
    PubMed     Text format    


  177. BLOEM BR, Marinus J, Almeida Q, Dibble L, et al
    Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations.
    Mov Disord. 2016 Mar 4. doi: 10.1002/mds.26572.
    PubMed     Text format     Abstract available



  178. Corrigenda: Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase.
    Mov Disord. 2016;31:433.
    PubMed     Text format    



  179. Abstracts of the Fifth Asian and Oceanian Parkinson's Disease and Movement Disorders Congress.
    Mov Disord. 2016;31 Suppl 1:S1-S103.
    PubMed     Text format    


  180. HERNANDEZ LF
    An A-PLAuse to a new assay that unveils previously undetected alpha-synucleinopathies.
    Mov Disord. 2016;31:301.
    PubMed     Text format    


  181. SWALLOW DM, Grosset KA, Grosset DG
    Nonmotor symptoms in patients without evidence of dopaminergic deficit.
    Mov Disord. 2016;31:429-30.
    PubMed     Text format    


  182. SPRENGER FS, Seppi K, Djamshidian A, Poewe W, et al
    Reply to "Nonmotor symptoms in subjects without evidence of dopaminergic deficit" authors: "Swallow DMA, Grosset KA, Grosset DG".
    Mov Disord. 2016;31:430-1.
    PubMed     Text format    


  183. MESTRE TA, Lang AE, Okun MS
    Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects.
    Mov Disord. 2016;31:290-6.
    PubMed     Text format     Abstract available


  184. OROPESA-RUIZ JM, Huertas-Fernandez I, Jesus S, Caceres-Redondo MT, et al
    Low serum uric acid levels in progressive supranuclear palsy.
    Mov Disord. 2016;31:402-5.
    PubMed     Text format     Abstract available


  185. WILE DJ, Dinelle K, Vafai N, McKenzie J, et al
    A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.
    Mov Disord. 2016;31:405-9.
    PubMed     Text format     Abstract available


  186. WALTER U, Muller JU, Rosche J, Kirsch M, et al
    Magnetic resonance-transcranial ultrasound fusion imaging: A novel tool for brain electrode location.
    Mov Disord. 2016;31:302-9.
    PubMed     Text format     Abstract available


    February 2016
  187. MOORS T, Paciotti S, Chiasserini D, Calabresi P, et al
    Lysosomal Dysfunction and alpha-Synuclein Aggregation in Parkinson's Disease: Diagnostic Links.
    Mov Disord. 2016 Feb 29. doi: 10.1002/mds.26562.
    PubMed     Text format     Abstract available


  188. NOWINSKI CJ, Siderowf A, Simuni T, Wortman C, et al
    Neuro-QoL health-related quality of life measurement system: Validation in Parkinson's disease.
    Mov Disord. 2016 Feb 26. doi: 10.1002/mds.26546.
    PubMed     Text format     Abstract available


  189. FIORENTINI C, Savoia P, Savoldi D, Bono F, et al
    Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
    Mov Disord. 2016 Feb 22. doi: 10.1002/mds.26581.
    PubMed     Text format     Abstract available


  190. BERG D, Postuma RB
    Diagnosis of Parkinson's disease: Imaging and genetics.
    Mov Disord. 2016 Feb 22. doi: 10.1002/mds.26544.
    PubMed     Text format    


  191. ERRO R, Bhatia KP
    Novel movement disorder society-Parkinson's disease criteria: What about SWEDD and genetic forms?
    Mov Disord. 2016 Feb 19. doi: 10.1002/mds.26538.
    PubMed     Text format    


  192. SPRENGER FS, Wurster I, Seppi K, Stockner H, et al
    Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor.
    Mov Disord. 2016 Feb 19. doi: 10.1002/mds.26515.
    PubMed     Text format     Abstract available


  193. NAVNTOFT CA, Dreyer JK
    How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum.
    Mov Disord. 2016 Feb 18. doi: 10.1002/mds.26579.
    PubMed     Text format     Abstract available


  194. MANENTI R, Brambilla M, Benussi A, Rosini S, et al
    Mild cognitive impairment in Parkinson's disease is improved by transcranial direct current stimulation combined with physical therapy.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26561.
    PubMed     Text format     Abstract available


  195. MULLER T, Kohlhepp W
    Hypomethylation in Parkinson's disease: An epigenetic drug effect?
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26560.
    PubMed     Text format    


  196. KLETTNER A, Richert E, Kuhlenbaumer G, Nolle B, et al
    Alpha synuclein and crystallin expression in human lens in Parkinson's disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26557.
    PubMed     Text format    


  197. CALIGIURI ME, Nistico R, Arabia G, Morelli M, et al
    Alterations of putaminal shape in de novo Parkinson's disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26550.
    PubMed     Text format     Abstract available


  198. ADLER CH, Hentz JG, Beach TG
    Assessing medication role on neuropathological findings in Parkinson's disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26536.
    PubMed     Text format    


  199. PALMA JA, Norcliffe-Kaufmann L, Kaufmann H
    An orthostatic hypotension mimic: The inebriation-like syndrome in Parkinson disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26516.
    PubMed     Text format    


  200. KLUGER BM, Herlofson K, Chou KL, Lou JS, et al
    Parkinson's disease-related fatigue: A case definition and recommendations for clinical research.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26511.
    PubMed     Text format     Abstract available


  201. HALL S, Surova Y, Ohrfelt A, Blennow K, et al
    Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
    Mov Disord. 2016 Feb 16. doi: 10.1002/mds.26578.
    PubMed     Text format     Abstract available


  202. RANGO M, Piatti M, Di Fonzo A, Ardolino G, et al
    Abnormal brain temperature in early-onset Parkinson's disease.
    Mov Disord. 2016 Feb 13. doi: 10.1002/mds.26548.
    PubMed     Text format    


  203. DING C, Ganesvaran G, Alty JE, Clissold BG, et al
    Study of levodopa response in Parkinson's disease: Observations on rates of motor progression.
    Mov Disord. 2016 Feb 13. doi: 10.1002/mds.26497.
    PubMed     Text format     Abstract available


  204. PINNA A, Ko WK, Costa G, Tronci E, et al
    Antidyskinetic effect of A and 5HT receptor ligands in two animal models of Parkinson's disease.
    Mov Disord. 2016 Feb 12. doi: 10.1002/mds.26475.
    PubMed     Text format     Abstract available


  205. TAYLOR S, Gafton J, Shah B, Pagano G, et al
    Progression of nonmotor symptoms in subgroups of patients with non-dopamine-deficient Parkinsonism.
    Mov Disord. 2016 Feb 11. doi: 10.1002/mds.26456.
    PubMed     Text format     Abstract available


  206. SOMEKO H, Hanajima R, Tsutsumi R, Tominaga N, et al
    Abnormal myocardial scintigraphy in a GTP cyclohydrolase 1 mutation carrier with Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26523.
    PubMed     Text format    


  207. MARRAS C, Chaudhuri KR
    Nonmotor features of Parkinson's disease subtypes.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26510.
    PubMed     Text format     Abstract available


  208. CASTELA I
    GABA: Inhibition brings new excitement in Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26507.
    PubMed     Text format    


  209. MOELTER ST, Weintraub D, Mace L, Cary M, et al
    Research consent capacity varies with executive function and memory in Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26469.
    PubMed     Text format     Abstract available


  210. CARR J, Guella I, Szu-Tu C, Boolay S, et al
    Double homozygous mutations (R275W and M432V) in the ParkinGene associated with late-onset Parkinson's disease.
    Mov Disord. 2016 Feb 10. doi: 10.1002/mds.26524.
    PubMed     Text format    


  211. GATT AP, Duncan OF, Attems J, Francis PT, et al
    Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency.
    Mov Disord. 2016 Feb 8. doi: 10.1002/mds.26513.
    PubMed     Text format     Abstract available


  212. PIHLSTROM L, Morset KR, Grimstad E, Vitelli V, et al
    A cumulative genetic risk score predicts progression in Parkinson's disease.
    Mov Disord. 2016 Feb 8. doi: 10.1002/mds.26505.
    PubMed     Text format     Abstract available


  213. ZHANG P, Shao XY, Qi GJ, Chen Q, et al
    Cdk5-Dependent Activation of Neuronal Inflammasomes in Parkinson's Disease.
    Mov Disord. 2016 Feb 8. doi: 10.1002/mds.26488.
    PubMed     Text format     Abstract available


  214. LEE JY, Yun EJ, Lee WW, Kim YK, et al
    Lateral geniculate atrophy in Parkinson's with visual hallucination: A trans-synaptic degeneration?
    Mov Disord. 2016 Feb 5. doi: 10.1002/mds.26533.
    PubMed     Text format     Abstract available


  215. MCINTOSH E, Gray A, Daniels J, Gill S, et al
    Cost-utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial.
    Mov Disord. 2016 Feb 5. doi: 10.1002/mds.26423.
    PubMed     Text format     Abstract available


  216. STEFANOVA N, Kordower JH, Wenning GK
    Preface.
    Mov Disord. 2016;31:151.
    PubMed     Text format    


  217. RICCIARDI L, Petrucci S, Di Giuda D, Serra L, et al
    The Contursi Family 20 Years Later: Intrafamilial Phenotypic Variability of the SNCA p.A53T Mutation.
    Mov Disord. 2016;31:257-8.
    PubMed     Text format    


  218. RUFFMANN C, Parkkinen L
    Gut Feelings About alpha-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?
    Mov Disord. 2016;31:193-202.
    PubMed     Text format     Abstract available


  219. CALO L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M, et al
    Synaptic failure and alpha-synuclein.
    Mov Disord. 2016;31:169-77.
    PubMed     Text format     Abstract available


  220. BERGSTROM AL, Kallunki P, Fog K
    Development of Passive Immunotherapies for Synucleinopathies.
    Mov Disord. 2016;31:203-13.
    PubMed     Text format     Abstract available


  221. VALERA E, Masliah E
    Combination therapies: The next logical Step for the treatment of synucleinopathies?
    Mov Disord. 2016;31:225-34.
    PubMed     Text format     Abstract available


  222. MCCANN H, Cartwright H, Halliday GM
    Neuropathology of alpha-synuclein propagation and braak hypothesis.
    Mov Disord. 2016;31:152-60.
    PubMed     Text format     Abstract available


  223. SCHNEEBERGER A, Tierney L, Mandler M
    Active immunization therapies for Parkinson's disease and multiple system atrophy.
    Mov Disord. 2016;31:214-24.
    PubMed     Text format     Abstract available


    January 2016
  224. VIDENOVIC A, Willis GL
    Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease?
    Mov Disord. 2016 Jan 30. doi: 10.1002/mds.26509.
    PubMed     Text format     Abstract available


  225. ANTONINI A, Fung VS, Boyd JT, Slevin JT, et al
    Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Mov Disord. 2016 Jan 28. doi: 10.1002/mds.26528.
    PubMed     Text format     Abstract available


  226. MALEKMOHAMMADI M, Herron J, Velisar A, Blumenfeld Z, et al
    Kinematic Adaptive Deep Brain Stimulation for Resting Tremor in Parkinson's Disease.
    Mov Disord. 2016 Jan 27. doi: 10.1002/mds.26482.
    PubMed     Text format    


  227. XILOURI M, Brekk OR, Stefanis L
    Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
    Mov Disord. 2016 Jan 27. doi: 10.1002/mds.26477.
    PubMed     Text format     Abstract available


  228. BHATTACHARYYA S, Bakshi R, Logan R, Ascherio A, et al
    Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease.
    Mov Disord. 2016 Jan 25. doi: 10.1002/mds.26483.
    PubMed     Text format     Abstract available


  229. ADLER CH, Dugger BN, Hentz JG, Hinni ML, et al
    Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings.
    Mov Disord. 2016 Jan 22. doi: 10.1002/mds.26476.
    PubMed     Text format     Abstract available


  230. CAKMAK YO
    Coffee consumption, smoking, and Parkinson's disease? The beneficial role of hydrogen sulfide.
    Mov Disord. 2016 Jan 14. doi: 10.1002/mds.26526.
    PubMed     Text format    


  231. MACEROLLO A, Chen JC, Korlipara P, Foltynie T, et al
    Dopaminergic treatment modulates sensory attenuation at the onset of the movement in Parkinson's disease: A test of a new framework for bradykinesia.
    Mov Disord. 2016 Jan 9. doi: 10.1002/mds.26493.
    PubMed     Text format     Abstract available


  232. SAITO Y, Shioya A, Sano T, Sumikura H, et al
    Lewy body pathology involves the olfactory cells in Parkinson's disease and related disorders.
    Mov Disord. 2016 Jan 8. doi: 10.1002/mds.26463.
    PubMed     Text format     Abstract available


  233. CARTA M, Cenci MA
    On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
    Mov Disord. 2016;31:149.
    PubMed     Text format    


  234. OLANOW CW, Poewe W
    Eldad Melamed 1942-2015: Ave atque--A memorial.
    Mov Disord. 2016;31:39-40.
    PubMed     Text format    


    December 2015
  235. REYNOLDS GO, Otto MW, Ellis TD, Cronin-Golomb A, et al
    The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.
    Mov Disord. 2015 Dec 30. doi: 10.1002/mds.26484.
    PubMed     Text format     Abstract available


  236. NOYCE AJ, Nalls MA
    Mendelian Randomization - the Key to Understanding Aspects of Parkinson's Disease Causation?
    Mov Disord. 2015 Dec 23. doi: 10.1002/mds.26492.
    PubMed     Text format     Abstract available


  237. MARTINEZ-MARTIN P, Leentjens AF, de Pedro-Cuesta J, Chaudhuri KR, et al
    Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease.
    Mov Disord. 2015 Dec 22. doi: 10.1002/mds.26522.
    PubMed     Text format     Abstract available


  238. WILLIAMS-GRAY CH
    A new biomarker for Parkinson's disease?
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26448.
    PubMed     Text format    


  239. FOO JN, Chung SJ, Tan LC, Liany H, et al
    Linking a genome-wide association study signal to a LRRK2 coding variant in Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26495.
    PubMed     Text format     Abstract available


  240. BERGARECHE A, Rodriguez-Oroz MC, Estanga A, Gorostidi A, et al
    DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26478.
    PubMed     Text format     Abstract available


  241. CHUNG SJ, Kim J, Lee HJ, Ryu HS, et al
    Alpha-synuclein in gastric and colonic mucosa in Parkinson's disease: Limited role as a biomarker.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26473.
    PubMed     Text format     Abstract available


  242. BROEN MP, Kohler S, Moonen AJ, Kuijf ML, et al
    Modeling anxiety in Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26461.
    PubMed     Text format     Abstract available


  243. UDUPA K, Chen R
    Role of dopamine in motor cortex plasticity in Parkinson's disease.
    Mov Disord. 2015 Dec 21. doi: 10.1002/mds.26451.
    PubMed     Text format    


  244. BARBAGALLO G, Sierra-Pena M, Nemmi F, Traon AP, et al
    Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease.
    Mov Disord. 2015 Dec 17. doi: 10.1002/mds.26471.
    PubMed     Text format     Abstract available


  245. DE VRIES NM, Nonnekes J, Bloem BR
    Toward affordable falls prevention in Parkinson's disease.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26474.
    PubMed     Text format    


  246. FRIEDMAN JH
    Editorial on: Pagonabarraga J, Martinez-Hora S, Fernandez de Bobadilla R et al. Minor hallucinations occur in drug-naive Parkinson's disease patients even from the premotor phase. Movement Disorders 2015; Available from: DOI: 10.1002/mds.26432.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26472.
    PubMed     Text format    


  247. BOEL JA, Odekerken VJ, Geurtsen GJ, Schmand BA, et al
    Psychiatric and social outcome after deep brain stimulation for advanced Parkinson's disease.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26468.
    PubMed     Text format     Abstract available


  248. SHUAIB UA, Rajput AH, Robinson CA, Rajput A, et al
    Neuroleptic-induced Parkinsonism: Clinicopathological study.
    Mov Disord. 2015 Dec 11. doi: 10.1002/mds.26467.
    PubMed     Text format     Abstract available


  249. DIEDERICH NJ, Goldman JG, Stebbins GT, Goetz CG, et al
    Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease.
    Mov Disord. 2015 Dec 9. doi: 10.1002/mds.26460.
    PubMed     Text format     Abstract available


  250. HENTZ JG, Mehta SH, Shill HA, Driver-Dunckley E, et al
    Simplified conversion method for unified Parkinson's disease rating scale motor examinations.
    Mov Disord. 2015;30:1967-70.
    PubMed     Text format     Abstract available


    November 2015
  251. SWANSON CR, Alcalay RN, Chen-Plotkin A
    Reply to letter: Plasma fasting cholesterol profiles and age at onset in Parkinson's disease.
    Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26447.
    PubMed     Text format    


  252. MASTERS JM, Bestwick J, Warner TT, Giovannoni G, et al
    Systematic review and meta-analysis of salivary protein concentration in Parkinson's disease.
    Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26462.
    PubMed     Text format    


  253. MAHLKNECHT P, Sprenger F, Seppi K, Poewe W, et al
    Plasma fasting cholesterol profiles and age at onset in Parkinson's disease.
    Mov Disord. 2015 Nov 19. doi: 10.1002/mds.26452.
    PubMed     Text format    


  254. ERRO R, Barone P
    Toward the premotor diagnosis of Parkinson's disease: Suggestions from a modelling study.
    Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26440.
    PubMed     Text format    


  255. KOJOVIC M, Bologna M, Edwards MJ, Rothwell JC, et al
    Reply to "Transcranial Magnetic Stimulation for Parkinson's Disease".
    Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26441.
    PubMed     Text format    


  256. VAN DEN NOORT M, Bosch P, Yeo S, Lim S, et al
    Transcranial Magnetic Stimulation for Parkinson's Disease.
    Mov Disord. 2015 Nov 17. doi: 10.1002/mds.26439.
    PubMed     Text format    


  257. NICOLETTI A, Zappia M
    Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
    Mov Disord. 2015;30:1854-6.
    PubMed     Text format    


  258. PAPAGIANNAKIS N, Xilouri M, Koros C, Stamelou M, et al
    Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients.
    Mov Disord. 2015;30:1830-4.
    PubMed     Text format     Abstract available


  259. LIM TT, Kluger BM, Rodriguez RL, Malaty IA, et al
    Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease.
    Mov Disord. 2015;30:1825-30.
    PubMed     Text format     Abstract available


  260. FUNG VS, Kordower JH
    Parkinson's disease and prion disease: Straining the comparison.
    Mov Disord. 2015;30:1727.
    PubMed     Text format    


  261. OLANOW CW, Bartus RT, Volpicelli-Daley LA, Kordower JH, et al
    Trophic factors for Parkinson's disease: To live or let die.
    Mov Disord. 2015;30:1715-24.
    PubMed     Text format     Abstract available


    October 2015
  262. SOLLA P, Fasano A, Cannas A, Marrosu F, et al
    Suicide and dopamine agonist withdrawal syndrome in Parkinson's disease.
    Mov Disord. 2015 Oct 10. doi: 10.1002/mds.26443.
    PubMed     Text format    


  263. ROSENTHAL LS, Drake D, Alcalay RN, Babcock D, et al
    The NINDS Parkinson's disease biomarkers program.
    Mov Disord. 2015 Oct 7. doi: 10.1002/mds.26438.
    PubMed     Text format     Abstract available


  264. BERG D, Postuma RB, Adler CH, Bloem BR, et al
    MDS research criteria for prodromal Parkinson's disease.
    Mov Disord. 2015;30:1600-11.
    PubMed     Text format     Abstract available


  265. POSTUMA RB, Berg D, Stern M, Poewe W, et al
    MDS clinical diagnostic criteria for Parkinson's disease.
    Mov Disord. 2015;30:1591-601.
    PubMed     Text format     Abstract available


  266. VAN STEENOVEN I, Aarsland D, Weintraub D
    Reply to letter to the editor 'Independent application of MoCA/MMSE conversion' by Armstrong et al.
    Mov Disord. 2015;30:1711.
    PubMed     Text format    


  267. ARMSTRONG MJ, Duff-Canning S, Psych C, Kowgier M, et al
    Independent application of montreal cognitive assessment/mini-mental state examination conversion.
    Mov Disord. 2015;30:1710-1.
    PubMed     Text format    


    September 2015
  268. PAGONABARRAGA J, Martinez-Horta S, Fernandez de Bobadilla R, Perez J, et al
    Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase.
    Mov Disord. 2015 Sep 26. doi: 10.1002/mds.26432.
    PubMed     Text format     Abstract available


  269. HAM JH, Lee JJ, Kim JS, Lee PH, et al
    Is Dominant-Side Onset Associated With a Better Motor Compensation in Parkinson's Disease?
    Mov Disord. 2015 Sep 26. doi: 10.1002/mds.26418.
    PubMed     Text format     Abstract available


  270. FARAG I, Sherrington C, Hayes A, Canning CG, et al
    Economic evaluation of a falls prevention exercise program among people With Parkinson's disease.
    Mov Disord. 2015 Sep 23. doi: 10.1002/mds.26420.
    PubMed     Text format     Abstract available


  271. SHAH N, Frey KA, L T M Muller M, Petrou M, et al
    Striatal and Cortical beta-Amyloidopathy and Cognition in Parkinson's Disease.
    Mov Disord. 2015 Sep 18. doi: 10.1002/mds.26369.
    PubMed     Text format     Abstract available


  272. SCHRAG A, Sauerbier A, Chaudhuri KR
    New clinical trials for nonmotor manifestations of Parkinson's disease.
    Mov Disord. 2015;30:1490-504.
    PubMed     Text format     Abstract available


  273. DU G, Liu T, Lewis MM, Kong L, et al
    Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
    Mov Disord. 2015 Sep 12. doi: 10.1002/mds.26417.
    PubMed     Text format     Abstract available


  274. QUINN EJ, Blumenfeld Z, Velisar A, Koop MM, et al
    Beta oscillations in freely moving Parkinson's subjects are attenuated during deep brain stimulation.
    Mov Disord. 2015 Sep 11. doi: 10.1002/mds.26376.
    PubMed     Text format     Abstract available


  275. SLOTNICK S, Ding Y, Glazman S, Durbin M, et al
    A novel retinal biomarker for Parkinson's disease: Quantifying the foveal pit with optical coherence tomography.
    Mov Disord. 2015 Sep 4. doi: 10.1002/mds.26411.
    PubMed     Text format     Abstract available


    August 2015
  276. GOLDMAN JG, Weintraub D
    Advances in the treatment of cognitive impairment in Parkinson's disease.
    Mov Disord. 2015 Aug 22. doi: 10.1002/mds.26352.
    PubMed     Text format     Abstract available


  277. MATA IF, Leverenz JB, Weintraub D, Trojanowski JQ, et al
    GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.
    Mov Disord. 2015 Aug 21. doi: 10.1002/mds.26359.
    PubMed     Text format     Abstract available


  278. CHAHINE LM, Weintraub D, Hawkins KA, Siderowf A, et al
    Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.
    Mov Disord. 2015 Aug 21. doi: 10.1002/mds.26373.
    PubMed     Text format     Abstract available


  279. CERASA A, Donzuso G, Morelli M, Mangone G, et al
    The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias.
    Mov Disord. 2015 Aug 14. doi: 10.1002/mds.26378.
    PubMed     Text format     Abstract available


  280. BLOEM BR, de Vries NM, Ebersbach G
    Nonpharmacological treatments for patients with Parkinson's disease.
    Mov Disord. 2015 Aug 14. doi: 10.1002/mds.26363.
    PubMed     Text format     Abstract available


  281. METMAN LV, Slavin KV
    Advances in functional neurosurgery for Parkinson's disease.
    Mov Disord. 2015 Aug 14. doi: 10.1002/mds.26338.
    PubMed     Text format     Abstract available


  282. NALLS MA, Keller MF, Hernandez DG, Chen L, et al
    Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI).
    Mov Disord. 2015 Aug 13. doi: 10.1002/mds.26374.
    PubMed     Text format     Abstract available


  283. POSTUMA RB, Adler CH, Dugger BN, Hentz JG, et al
    REM sleep behavior disorder and neuropathology in Parkinson's disease.
    Mov Disord. 2015 Aug 12. doi: 10.1002/mds.26347.
    PubMed     Text format     Abstract available


  284. RAJ KUMAR K
    Targeting glucocerebrosidase: Reduced enzymatic activity and Parkinson's disease.
    Mov Disord. 2015 Aug 11. doi: 10.1002/mds.26379.
    PubMed     Text format    


  285. SCHUFF N, Wu IW, Buckley S, Foster ED, et al
    Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits.
    Mov Disord. 2015 Aug 11. doi: 10.1002/mds.26325.
    PubMed     Text format     Abstract available


  286. BRENNAN L, Siderowf A, Rubright JD, Rick J, et al
    Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire.
    Mov Disord. 2015 Aug 7. doi: 10.1002/mds.26339.
    PubMed     Text format     Abstract available


  287. PIHLSTROM L, Toft M
    Cumulative genetic risk and age at onset in Parkinson's disease.
    Mov Disord. 2015 Aug 3. doi: 10.1002/mds.26366.
    PubMed     Text format    


  288. VIRMANI T, Moskowitz CB, Vonsattel JP, Fahn S, et al
    Clinicopathological characteristics of freezing of gait in autopsy-confirmed Parkinson's disease.
    Mov Disord. 2015 Aug 3. doi: 10.1002/mds.26346.
    PubMed     Text format     Abstract available


  289. MA Y, Johnston TH, Peng S, Zuo C, et al
    Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.
    Mov Disord. 2015;30:1283-8.
    PubMed     Text format     Abstract available


    July 2015
  290. SCHRAG A
    A new scale for the assessment of pain in Parkinson's disease.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26353.
    PubMed     Text format    


  291. MISCHLEY LK, Leverenz JB, Lau RC, Polissar NL, et al
    A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26351.
    PubMed     Text format     Abstract available


  292. SERAJI-BOZORGZAD N, Bao F, George E, Krstevska S, et al
    Longitudinal study of the substantia nigra in Parkinson disease: A high-field H-MR spectroscopy imaging study.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26323.
    PubMed     Text format     Abstract available


  293. GESQUIERE-DANDO A, Guedj E, Loundou A, Carron R, et al
    A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation.
    Mov Disord. 2015 Jul 31. doi: 10.1002/mds.26349.
    PubMed     Text format     Abstract available


  294. UDUPA K, Ghahremani A, Chen R
    Are we close to the advent of closed loop deep brain stimulation in Parkinson's disease?
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26343.
    PubMed     Text format    


  295. MENDES A, Goncalves A, Vila-Cha N, Moreira I, et al
    Appendectomy may delay Parkinson's disease Onset.
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26311.
    PubMed     Text format     Abstract available


  296. RAMIREZ A
    Population-Based Genetic Studies: The Search for Causative Variants in Parkinson's Disease.
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26341.
    PubMed     Text format    


  297. POSTUMA RB
    Can Parkinson's Disease Come From the Gut?
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26337.
    PubMed     Text format    


  298. WILLIAMS-GRAY C
    Seeing Is Believing: Alpha-Synuclein Oligomers in Parkinson's Disease Brain.
    Mov Disord. 2015 Jul 30. doi: 10.1002/mds.26335.
    PubMed     Text format    


  299. KALIA LV, Kalia SK, Lang AE
    Disease-modifying strategies for Parkinson's disease.
    Mov Disord. 2015 Jul 24. doi: 10.1002/mds.26354.
    PubMed     Text format     Abstract available


  300. SWANSON CR, Berlyand Y, Xie SX, Alcalay RN, et al
    Plasma Apolipoprotein A1 Associates With Age at Onset and Motor Severity in Early Parkinson's Disease Patients.
    Mov Disord. 2015 Jul 24. doi: 10.1002/mds.26290.
    PubMed     Text format     Abstract available


  301. DUNCAN GW, Firbank MJ, Yarnall AJ, Khoo TK, et al
    Gray and white matter imaging: A biomarker for cognitive impairment in early Parkinson's disease?
    Mov Disord. 2015 Jul 22. doi: 10.1002/mds.26312.
    PubMed     Text format     Abstract available


  302. REHMAN AF, Dhamija R, Williams ES, Barrett MJ, et al
    22q11.2 deletion syndrome presenting with early-onset Parkinson's disease.
    Mov Disord. 2015 Jul 21. doi: 10.1002/mds.26305.
    PubMed     Text format    


  303. OZ G
    MR Spectroscopy: A Longitudinal Biomarker for Substantia Nigra Pathology in Parkinson's Disease?
    Mov Disord. 2015 Jul 17. doi: 10.1002/mds.26322.
    PubMed     Text format    


  304. ZORKO N, Kojovic M, Flisar D, Pirtosek Z, et al
    Suicide in Parkinson's Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel.
    Mov Disord. 2015 Jul 17. doi: 10.1002/mds.26315.
    PubMed     Text format    


  305. LOU Y, Huang P, Li D, Cen Z, et al
    Altered brain network centrality in depressed Parkinson's disease patients.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26321.
    PubMed     Text format     Abstract available


  306. FERNANDEZ HH, Standaert DG, Chatamra K, Benesh JA, et al
    Reply to letter: Suicide in Parkinson's disease patients treated with levodopa-carbidopa Intestinal Gel.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26316.
    PubMed     Text format    


  307. KESHAVARZIAN A, Green SJ, Engen PA, Voigt RM, et al
    Colonic bacterial composition in Parkinson's disease.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26307.
    PubMed     Text format     Abstract available


  308. BRUNDIN P, Atkin G, Lamberts JT
    Basic science breaks through: New therapeutic advances in Parkinson's disease.
    Mov Disord. 2015 Jul 16. doi: 10.1002/mds.26332.
    PubMed     Text format     Abstract available


  309. LOPANE G, Mellone S, Chiari L, Cortelli P, et al
    Dyskinesia detection and monitoring by a single sensor in patients with Parkinson's disease.
    Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26313.
    PubMed     Text format     Abstract available


  310. BAIG F, Lawton M, Rolinski M, Ruffmann C, et al
    Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives.
    Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26281.
    PubMed     Text format     Abstract available


  311. SCHMITT I, Kaut O, Khazneh H, deBoni L, et al
    L-dopa increases alpha-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro.
    Mov Disord. 2015 Jul 14. doi: 10.1002/mds.26319.
    PubMed     Text format     Abstract available


  312. STEELE JC, Wresch R, Hanlon SD, Keystone J, et al
    A unique retinal epitheliopathy is associated with amyotrophic lateral sclerosis/Parkinsonism-Dementia complex of Guam.
    Mov Disord. 2015 Jul 7. doi: 10.1002/mds.26264.
    PubMed     Text format     Abstract available


  313. SANTANGELO G, Trojano L, Barone P, Vitale C, et al
    Cortical thickness in Parkinsonians with impulse control disorders: A comment.
    Mov Disord. 2015 Jul 7. doi: 10.1002/mds.26262.
    PubMed     Text format    


  314. BURCIU RG, Ofori E, Shukla P, Planetta PJ, et al
    Distinct patterns of brain activity in progressive supranuclear palsy and Parkinson's disease.
    Mov Disord. 2015 Jul 6. doi: 10.1002/mds.26294.
    PubMed     Text format     Abstract available


  315. DAVID FJ, Robichaud JA, Leurgans SE, Poon C, et al
    Exercise Improves Cognition in Parkinson's Disease: The PRET-PD Randomized, Clinical Trial.
    Mov Disord. 2015 Jul 6. doi: 10.1002/mds.26291.
    PubMed     Text format     Abstract available


  316. SCHEPERJANS F
    Reply to letter to the editor by Assoc. Prof. Yusuf Ozgur Cakmak, MD, PhD.
    Mov Disord. 2015;30:1151-3.
    PubMed     Text format    


    June 2015
  317. CURTZE C, Nutt JG, Carlson-Kuhta P, Mancini M, et al
    Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease.
    Mov Disord. 2015 Jun 12. doi: 10.1002/mds.26269.
    PubMed     Text format     Abstract available


  318. MURATA M, Hasegawa K, Kanazawa I, Fukasaka J, et al
    Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Mov Disord. 2015 Jun 12. doi: 10.1002/mds.26286.
    PubMed     Text format     Abstract available


  319. FRANCIOTTI R, Delli Pizzi S, Perfetti B, Tartaro A, et al
    Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy.
    Mov Disord. 2015 Jun 12. doi: 10.1002/mds.26285.
    PubMed     Text format     Abstract available


  320. GEGG ME, Sweet L, Wang BH, Shihabuddin LS, et al
    No evidence for substrate accumulation in Parkinson brains with GBA mutations.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26278.
    PubMed     Text format     Abstract available


  321. ROCHESTER L, Espay AJ
    Multidisciplinary rehabilitation in Parkinson's disease: A milestone with future challenges.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26277.
    PubMed     Text format    


  322. ROSSI M, Perez-Lloret S, Millar Vernetti P, Drucaroff L, et al
    Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's Disease.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26276.
    PubMed     Text format     Abstract available


  323. FORJAZ MJ, Ayala A, Testa CM, Bain PG, et al
    Proposing a Parkinson's Disease-Specific Tremor Scale From the MDS-UPDRS.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26271.
    PubMed     Text format     Abstract available


  324. CHAUDHURI KR, Rizos A, Trenkwalder C, Rascol O, et al
    King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26270.
    PubMed     Text format     Abstract available


  325. WAKEMAN DR
    Autologous iPSC-Derived Dopamine Neuron Grafts Show Considerable Promise in a Nonhuman Primate Model of Parkinson's Disease.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26267.
    PubMed     Text format    


  326. MONTICONE M, Ambrosini E, Laurini A, Rocca B, et al
    In-patient multidisciplinary rehabilitation for Parkinson's disease: A randomized controlled trial.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26256.
    PubMed     Text format     Abstract available


  327. CERAVOLO R, Antonini A, Frosini D, De Iuliis A, et al
    Nigral anatomy and striatal denervation in genetic Parkinsonism: A family report.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26255.
    PubMed     Text format    


  328. SIMUNI T, Caspell-Garcia C, Coffey C, Chahine LM, et al
    Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study.
    Mov Disord. 2015 Jun 11. doi: 10.1002/mds.26248.
    PubMed     Text format     Abstract available


  329. KOTAGAL V, Bohnen NI, Muller ML, Koeppe RA, et al
    Educational Attainment and Motor Burden in Parkinson's Disease.
    Mov Disord. 2015 Jun 10. doi: 10.1002/mds.26272.
    PubMed     Text format     Abstract available



  330. Abstracts of the Nineteenth International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2015;30 Suppl 1:S1-S642.
    PubMed     Text format    


  331. HORNYKIEWICZ O
    50 years of levodopa.
    Mov Disord. 2015;30:1008.
    PubMed     Text format    


  332. FAHN S
    Reply: Oleh Hornykiewicz's contribution to the l-dopa story.
    Mov Disord. 2015;30:1008-9.
    PubMed     Text format    


    May 2015
  333. CARECCHIO M, Schneider SA
    GTP cyclohydrolase 1 mutations and Parkinson's disease: New insights beyond DOPA-responsive dystonia.
    Mov Disord. 2015 May 27. doi: 10.1002/mds.26283.
    PubMed     Text format    


  334. BURN DJ
    The treatment of mild cognitive impairment associated with Parkinson's.
    Mov Disord. 2015 May 23. doi: 10.1002/mds.26245.
    PubMed     Text format    


  335. LOHMANN E, Coquel AS, Honore A, Gurvit H, et al
    A new F-box protein 7 gene mutation causing typical Parkinson's disease.
    Mov Disord. 2015 May 23. doi: 10.1002/mds.26266.
    PubMed     Text format     Abstract available


  336. ROSA M, Arlotti M, Ardolino G, Cogiamanian F, et al
    Adaptive deep brain stimulation in a freely moving parkinsonian patient.
    Mov Disord. 2015 May 21. doi: 10.1002/mds.26241.
    PubMed     Text format    


  337. VIZCARRA JA, Lang AE, Sethi KD, Espay AJ, et al
    Vascular Parkinsonism: Deconstructing a Syndrome.
    Mov Disord. 2015 May 21. doi: 10.1002/mds.26263.
    PubMed     Text format     Abstract available


  338. CAKMAK YO
    Provotella-derived hydrogen sulfide, constipation, and neuroprotection in Parkinson's disease.
    Mov Disord. 2015 May 13. doi: 10.1002/mds.26258.
    PubMed     Text format    


  339. NOYCE AJ, Mencacci NE, Schrag A, Bestwick JP, et al
    Web-based assessment of Parkinson's prodromal markers identifies GBA variants.
    Mov Disord. 2015 May 13. doi: 10.1002/mds.26249.
    PubMed     Text format    


  340. PONT-SUNYER C, Bressman S, Raymond D, Glickman A, et al
    Disclosure of research results in genetic studies of Parkinson's disease caused by LRRK2 mutations.
    Mov Disord. 2015 May 7. doi: 10.1002/mds.26250.
    PubMed     Text format     Abstract available


  341. GUARDIA-LAGUARTA C, Area-Gomez E, Schon EA, Przedborski S, et al
    A new role for alpha-Synuclein in Parkinson's disease: Alteration of ER-Mitochondrial communication.
    Mov Disord. 2015 May 7. doi: 10.1002/mds.26239.
    PubMed     Text format     Abstract available


    April 2015
  342. ZHANG Y, Wu IW, Buckley S, Coffey CS, et al
    Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease.
    Mov Disord. 2015 Apr 29. doi: 10.1002/mds.26251.
    PubMed     Text format     Abstract available


  343. LILL CM, Hansen J, Olsen JH, Binder H, et al
    Impact of Parkinson's disease risk loci on age at onset.
    Mov Disord. 2015 Apr 25. doi: 10.1002/mds.26237.
    PubMed     Text format     Abstract available


  344. MAMIKONYAN E, Xie SX, Melvin E, Weintraub D, et al
    Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study.
    Mov Disord. 2015 Apr 25. doi: 10.1002/mds.26236.
    PubMed     Text format     Abstract available


  345. WEISS PH, Herzog J, Potter-Nerger M, Falk D, et al
    Subthalamic nucleus stimulation improves parkinsonian gait via brainstem locomotor centers.
    Mov Disord. 2015 Apr 25. doi: 10.1002/mds.26229.
    PubMed     Text format     Abstract available


  346. WEISSBACH A, Baumer T, Rosales R, Lee LV, et al
    Neurophysiological fingerprints of x-linked dystonia-parkinsonism: A model basal ganglia disease.
    Mov Disord. 2015 Apr 25. doi: 10.1002/mds.26224.
    PubMed     Text format    


  347. KASTEN M, Klein C
    Genetic risk loci for Parkinson's disease: Moving from state to trait?
    Mov Disord. 2015 Apr 23. doi: 10.1002/mds.26246.
    PubMed     Text format    


  348. PARK JS, Blair NF, Sue CM
    The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.
    Mov Disord. 2015 Apr 21. doi: 10.1002/mds.26243.
    PubMed     Text format     Abstract available


  349. HANAGASI HA
    The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study.
    Mov Disord. 2015 Apr 16. doi: 10.1002/mds.26235.
    PubMed     Text format    


  350. MOLLENHAUER B
    Prediagnostic presentation of Parkinson's disease in primary care: A case-control study.
    Mov Disord. 2015 Apr 16. doi: 10.1002/mds.26234.
    PubMed     Text format    


  351. PETROU M, Dwamena BA, Foerster BR, MacEachern MP, et al
    Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review.
    Mov Disord. 2015 Apr 16. doi: 10.1002/mds.26191.
    PubMed     Text format     Abstract available


  352. UDUPA K, Fox SH
    Placebo effect in Parkinson's disease: Harnessing the mind in the treatment of PD.
    Mov Disord. 2015 Apr 8. doi: 10.1002/mds.26222.
    PubMed     Text format    


  353. STURKENBOOM IH, Hendriks JC, Graff MJ, Adang EM, et al
    Economic evaluation of occupational therapy in Parkinson's disease: A randomized controlled trial.
    Mov Disord. 2015 Apr 8. doi: 10.1002/mds.26217.
    PubMed     Text format     Abstract available


  354. VERHAGEN METMAN L, Stover N, Chen C, Cowles VE, et al
    Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
    Mov Disord. 2015 Apr 2. doi: 10.1002/mds.26219.
    PubMed     Text format     Abstract available


  355. ERRO R
    VPS35 and EIF4G1 interactions and novel candidate genes for PD: from genes to pathways and back.
    Mov Disord. 2015;30:499.
    PubMed     Text format    


  356. FASANO A, Liu LW, Poon YY, Lang AE, et al
    Initiating intrajejunal infusion of levodopa/carbidopa intestinal gel: an outpatient model.
    Mov Disord. 2015;30:598-9.
    PubMed     Text format    


  357. NUTT JG
    Continuous levodopa infusion is better-for now.
    Mov Disord. 2015;30:443-5.
    PubMed     Text format    


  358. POEWE W, Hauser RA, Lang A
    Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
    Mov Disord. 2015;30:589-92.
    PubMed     Text format     Abstract available


    March 2015
  359. OZINGA SJ, Machado AG, Miller Koop M, Rosenfeldt AB, et al
    Objective assessment of postural stability in Parkinson's disease using mobile technology.
    Mov Disord. 2015 Mar 25. doi: 10.1002/mds.26214.
    PubMed     Text format     Abstract available


  360. BEKRIS LM, Tsuang DW, Peskind ER, Yu CE, et al
    Cerebrospinal fluid Abeta levels and APP processing pathway genes in Parkinson's disease.
    Mov Disord. 2015 Mar 24. doi: 10.1002/mds.26172.
    PubMed     Text format     Abstract available


  361. RIEU I, Martinez-Martin P, Pereira B, De Chazeron I, et al
    International validation of a behavioral scale in Parkinson's disease without dementia.
    Mov Disord. 2015 Mar 21. doi: 10.1002/mds.26223.
    PubMed     Text format     Abstract available


  362. DEN BROK MG, Dalen JW, van Gool WA, Moll van Charante EP, et al
    Apathy in Parkinson's disease: A systematic review and meta-analysis.
    Mov Disord. 2015 Mar 18. doi: 10.1002/mds.26208.
    PubMed     Text format     Abstract available


  363. ZANJANI A, Zakzanis KK, Daskalakis ZJ, Chen R, et al
    Repetitive transcranial magnetic stimulation of the primary motor cortex in the treatment of motor signs in Parkinson's disease: A quantitative review of the literature.
    Mov Disord. 2015 Mar 18. doi: 10.1002/mds.26206.
    PubMed     Text format     Abstract available


  364. CHIKINA MD, Gerald CP, Li X, Ge Y, et al
    Low-Variance RNAs Identify Parkinson's Disease Molecular Signature in Blood.
    Mov Disord. 2015 Mar 18. doi: 10.1002/mds.26205.
    PubMed     Text format     Abstract available


  365. ERRO R, Bhatia KP, Tinazzi M
    Parkinsonism following neuroleptic exposure: A double-hit hypothesis?
    Mov Disord. 2015 Mar 18. doi: 10.1002/mds.26209.
    PubMed     Text format     Abstract available


  366. NALLS MA, Escott-Price V, Williams NM, Lubbe S, et al
    Genetic risk and age in Parkinson's: Continuum not stratum.
    Mov Disord. 2015 Mar 17. doi: 10.1002/mds.26192.
    PubMed     Text format     Abstract available


  367. GIANNOCCARO MP, Donadio V, Incensi A, Pizza F, et al
    Skin biopsy and I-123 MIBG scintigraphy findings in idiopathic Parkinson's disease and parkinsonism: A comparative study.
    Mov Disord. 2015 Mar 17. doi: 10.1002/mds.26189.
    PubMed     Text format     Abstract available


  368. MATSUMOTO M
    Dopamine signals and physiological origin of cognitive dysfunction in Parkinson's disease.
    Mov Disord. 2015 Mar 15. doi: 10.1002/mds.26177.
    PubMed     Text format     Abstract available


  369. REITER E, Mueller C, Pinter B, Krismer F, et al
    Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism.
    Mov Disord. 2015 Mar 15. doi: 10.1002/mds.26171.
    PubMed     Text format     Abstract available


  370. CASTELLANOS G, Fernandez-Seara MA, Lorenzo-Betancor O, Ortega-Cubero S, et al
    Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease.
    Mov Disord. 2015 Mar 15. doi: 10.1002/mds.26201.
    PubMed     Text format     Abstract available


  371. SIXEL-DORING F, Lohmann K, Klein C, Trenkwalder C, et al
    REM sleep-associated motor behaviors in Parkinson's disease patients with heterozygous Parkin mutations.
    Mov Disord. 2015 Mar 15. doi: 10.1002/mds.26193.
    PubMed     Text format    


  372. FOX SH, Marras C
    Orthostatic hypotension in Parkinsonism: What is it and how can we treat it?
    Mov Disord. 2015 Mar 11. doi: 10.1002/mds.26179.
    PubMed     Text format    


  373. SOLLA P, Bortolato M, Cannas A, Mulas CS, et al
    Paraphilias and paraphilic disorders in Parkinson's disease: A systematic review of the literature.
    Mov Disord. 2015 Mar 11. doi: 10.1002/mds.26157.
    PubMed     Text format     Abstract available


  374. MADHYASTHA TM, Askren MK, Boord P, Zhang J, et al
    Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease.
    Mov Disord. 2015 Mar 11. doi: 10.1002/mds.26128.
    PubMed     Text format     Abstract available


  375. REIMAO S, Pita Lobo P, Neutel D, Guedes LC, et al
    Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Mov Disord. 2015 Mar 11. doi: 10.1002/mds.26182.
    PubMed     Text format     Abstract available


  376. BRONSTEIN JM, Paul K, Yang L, Haas RH, et al
    Platelet mitochondrial activity and pesticide exposure in early Parkinson's disease.
    Mov Disord. 2015 Mar 11. doi: 10.1002/mds.26164.
    PubMed     Text format     Abstract available


  377. SIRI C, Cilia R, Reali E, Pozzi B, et al
    Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders.
    Mov Disord. 2015 Mar 11. doi: 10.1002/mds.26160.
    PubMed     Text format     Abstract available


  378. KOJOVIC M, Kassavetis P, Bologna M, Parees I, et al
    Transcranial magnetic stimulation follow-up study in early Parkinson's disease: A decline in compensation with disease progression?
    Mov Disord. 2015 Mar 5. doi: 10.1002/mds.26167.
    PubMed     Text format     Abstract available


  379. WEINTRAUB D, Simuni T, Caspell-Garcia C, Coffey C, et al
    Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.
    Mov Disord. 2015 Mar 4. doi: 10.1002/mds.26170.
    PubMed     Text format     Abstract available


  380. BARRETT MJ, Hac NE, Yan G, Harrison MB, et al
    Relationship of age of onset and family history in Parkinson disease.
    Mov Disord. 2015 Mar 4. doi: 10.1002/mds.26166.
    PubMed     Text format     Abstract available


  381. SOMMERAUER M, Imbach LL, Jarallah M, Baumann CR, et al
    Diminished event-related cortical arousals and altered heart rate response in Parkinson's disease.
    Mov Disord. 2015 Mar 4. doi: 10.1002/mds.26165.
    PubMed     Text format     Abstract available


  382. BLANCHET PJ, Pourcher E
    In memoriam: Paul J. Bedard, MD PhD: January 19, 1942-December 26, 2014.
    Mov Disord. 2015;30:299-300.
    PubMed     Text format    


  383. ZAVALA B, Zaghloul K, Brown P
    The subthalamic nucleus, oscillations, and conflict.
    Mov Disord. 2015;30:328-38.
    PubMed     Text format     Abstract available


  384. GOLDMAN JG, Holden S, Ouyang B, Bernard B, et al
    Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests?
    Mov Disord. 2015;30:402-6.
    PubMed     Text format     Abstract available


    February 2015
  385. THOBOIS S
    USP30: A new promising target for Parkinson's disease?
    Mov Disord. 2015 Feb 20. doi: 10.1002/mds.26185.
    PubMed     Text format    


  386. SCHULZ-SCHAEFFER WJ, Margraf NG, Munser S, Wrede A, et al
    Effect of Neurostimulation on Camptocormia in Parkinson's Disease Depends on Symptom Duration.
    Mov Disord. 2015 Feb 12. doi: 10.1002/mds.26081.
    PubMed     Text format     Abstract available


  387. PALMA JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, et al
    Orthostatic Hypotension in Parkinson Disease: How Much You Fall or How Low You Go?
    Mov Disord. 2015 Feb 12. doi: 10.1002/mds.26079.
    PubMed     Text format     Abstract available


  388. SRIVATSAL S, Cholerton B, Leverenz JB, Wszolek ZK, et al
    Cognitive profile of LRRK2-related Parkinson's disease.
    Mov Disord. 2015 Feb 4. doi: 10.1002/mds.26161.
    PubMed     Text format     Abstract available


  389. PAHWA R, Tanner CM, Hauser RA, Sethi K, et al
    Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Mov Disord. 2015 Feb 4. doi: 10.1002/mds.26159.
    PubMed     Text format     Abstract available


  390. BIUNDO R, Weis L, Facchini S, Formento-Dojot P, et al
    Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease.
    Mov Disord. 2015 Feb 4. doi: 10.1002/mds.26154.
    PubMed     Text format     Abstract available


  391. GORDON PH, Mehal JM, Holman RC, Bartholomew ML, et al
    Incidence and prevalence of Parkinson's disease among Navajo people living in the Navajo nation.
    Mov Disord. 2015 Feb 4. doi: 10.1002/mds.26147.
    PubMed     Text format     Abstract available


  392. CHESHIRE P, Ayton S, Bertram KL, Ling H, et al
    Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
    Mov Disord. 2015 Feb 4. doi: 10.1002/mds.26144.
    PubMed     Text format     Abstract available


  393. ERRO R, Picillo M, Amboni M, Moccia M, et al
    Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease.
    Mov Disord. 2015 Feb 4. doi: 10.1002/mds.26076.
    PubMed     Text format     Abstract available


  394. PAYER DE, Guttman M, Kish SJ, Tong J, et al
    [(11) C]-(+)-PHNO PET imaging of dopamine D2/3 receptors in Parkinson's disease with impulse control disorders.
    Mov Disord. 2015;30:160-6.
    PubMed     Text format     Abstract available


  395. SINGLETON A
    X-linked Parkinson's disease.
    Mov Disord. 2015;30:196.
    PubMed     Text format    


  396. WEST AB
    Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic.
    Mov Disord. 2015;30:180-9.
    PubMed     Text format     Abstract available


  397. SHARP ME, Caccappolo E, Mejia-Santana H, Tang MX, et al
    The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.
    Mov Disord. 2015;30:278-83.
    PubMed     Text format     Abstract available


    January 2015
  398. SAMUEL M, Rodriguez-Oroz M, Antonini A, Brotchie JM, et al
    Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.
    Mov Disord. 2015 Jan 21. doi: 10.1002/mds.26099.
    PubMed     Text format     Abstract available


  399. BAGGIO HC, Segura B, Garrido-Millan JL, Marti MJ, et al
    Resting-state frontostriatal functional connectivity in Parkinson's disease-related apathy.
    Mov Disord. 2015 Jan 20. doi: 10.1002/mds.26137.
    PubMed     Text format     Abstract available


  400. ANTONIADES CA, Demeyere N, Kennard C, Humphreys GW, et al
    Antisaccades and executive dysfunction in early drug-naive Parkinson's disease: The discovery study.
    Mov Disord. 2015 Jan 20. doi: 10.1002/mds.26134.
    PubMed     Text format     Abstract available


  401. PETERSEN MS, Bech S, Nosova E, Aasly J, et al
    Familial aggregation of Parkinson's disease in the Faroe Islands.
    Mov Disord. 2015 Jan 20. doi: 10.1002/mds.26132.
    PubMed     Text format     Abstract available


  402. VAN MIERLO TJ, Chung C, Foncke EM, Berendse HW, et al
    Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume.
    Mov Disord. 2015 Jan 20. doi: 10.1002/mds.26112.
    PubMed     Text format     Abstract available


  403. MURPHY KE, Gysbers AM, Abbott SK, Spiro AS, et al
    Lysosomal-associated membrane protein 2 Isoforms Are Differentially Affected in Early Parkinson's Disease.
    Mov Disord. 2015 Jan 16. doi: 10.1002/mds.26141.
    PubMed     Text format     Abstract available


  404. WANG HC, Lin CC, Lau CI, Chang A, et al
    Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease.
    Mov Disord. 2015 Jan 16. doi: 10.1002/mds.26136.
    PubMed     Text format     Abstract available


  405. SMULDERS K, Esselink RA, Bloem BR, Cools R, et al
    Freezing of gait in Parkinson's disease is related to impaired motor switching during stepping.
    Mov Disord. 2015 Jan 16. doi: 10.1002/mds.26133.
    PubMed     Text format     Abstract available


  406. VERCRUYSSE S, Leunissen I, Vervoort G, Vandenberghe W, et al
    Microstructural changes in white matter associated with freezing of gait in Parkinson's disease.
    Mov Disord. 2015 Jan 16. doi: 10.1002/mds.26130.
    PubMed     Text format     Abstract available


  407. KORHONEN P, Kuoppamaki M, Prami T, Hoti F, et al
    Entacapone and Prostate Cancer Risk in Patients With Parkinson's Disease.
    Mov Disord. 2015 Jan 16. doi: 10.1002/mds.26140.
    PubMed     Text format     Abstract available


  408. HUANG X, Alonso A, Guo X, Umbach DM, et al
    Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study.
    Mov Disord. 2015 Jan 14. doi: 10.1002/mds.26152.
    PubMed     Text format     Abstract available


  409. BEAULIEU-BOIRE I, Lang AE
    Behavioral effects of levodopa.
    Mov Disord. 2015;30:90-102.
    PubMed     Text format     Abstract available


  410. AQUINO CC, Fox SH
    Clinical spectrum of levodopa-induced complications.
    Mov Disord. 2015;30:80-9.
    PubMed     Text format     Abstract available


  411. LEES AJ, Tolosa E, Olanow CW
    Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Mov Disord. 2015;30:19-36.
    PubMed     Text format     Abstract available


  412. POEWE W, Antonini A
    Novel formulations and modes of delivery of levodopa.
    Mov Disord. 2015;30:114-20.
    PubMed     Text format     Abstract available


  413. MOSHAROV EV, Borgkvist A, Sulzer D
    Presynaptic effects of levodopa and their possible role in dyskinesia.
    Mov Disord. 2015;30:45-53.
    PubMed     Text format     Abstract available


  414. GERSHANIK OS
    Improving L-dopa therapy: the development of enzyme inhibitors.
    Mov Disord. 2015;30:103-13.
    PubMed     Text format     Abstract available


  415. KO JH, Lerner RP, Eidelberg D
    Effects of levodopa on regional cerebral metabolism and blood flow.
    Mov Disord. 2015;30:54-63.
    PubMed     Text format     Abstract available


    December 2014
  416. FORJAZ MJ, Ayala A, Martinez-Martin P, Dujardin K, et al
    Is the Parkinson anxiety scale comparable across raters?
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26111.
    PubMed     Text format     Abstract available


  417. GALNA B, Lord S, Burn DJ, Rochester L, et al
    Progression of gait dysfunction in incident Parkinson's disease: Impact of medication and phenotype.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26110.
    PubMed     Text format     Abstract available


  418. OKAI D, Askey-Jones S, Samuel M, David AS, et al
    Predictors of response to a cognitive behavioral intervention for impulse control behaviors in Parkinson's disease.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26108.
    PubMed     Text format     Abstract available


  419. MARINUS J, van Hilten JJ
    The significance of motor (A)symmetry in Parkinson's disease.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26107.
    PubMed     Text format     Abstract available


  420. TUNC S, Graf J, Tadic V, Bruggemann N, et al
    A population-based study on combined markers for early Parkinson's disease.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26100.
    PubMed     Text format     Abstract available


  421. HU X, Song X, Yuan Y, Li E, et al
    Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26087.
    PubMed     Text format     Abstract available


  422. PIHLSTROM L, Berge V, Rengmark A, Toft M, et al
    Parkinson's disease correlates with promoter methylation in the alpha-synuclein gene.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26073.
    PubMed     Text format     Abstract available


  423. SHARER JD, Leon-Sarmiento FE, Morley JF, Weintraub D, et al
    Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26126.
    PubMed     Text format     Abstract available


  424. WANG L, Evatt ML, Maldonado LG, Perry WR, et al
    Vitamin D from different sources is inversely associated with Parkinson disease.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26117.
    PubMed     Text format     Abstract available


  425. VIZCARRA JA, Wilson-Perez HE, Espay AJ
    The power in numbers: Gut microbiota in Parkinson's disease.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26116.
    PubMed     Text format    


  426. POTTER-NERGER M, Govender S, Deuschl G, Volkmann J, et al
    Selective changes of ocular vestibular myogenic potentials in Parkinson's disease.
    Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26114.
    PubMed     Text format     Abstract available


  427. FERNANDEZ HH, Standaert DG, Hauser RA, Lang AE, et al
    Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results.
    Mov Disord. 2014 Dec 24. doi: 10.1002/mds.26123.
    PubMed     Text format     Abstract available


  428. ROWLAND NC, Starr PA, Larson PS, Ostrem JL, et al
    Combining cell transplants or gene therapy with deep brain stimulation for Parkinson's disease.
    Mov Disord. 2014 Dec 17. doi: 10.1002/mds.26083.
    PubMed     Text format     Abstract available


  429. OLANOW CW
    Levodopa: Effect on cell death and the natural history of Parkinson's disease.
    Mov Disord. 2014 Dec 11. doi: 10.1002/mds.26119.
    PubMed     Text format     Abstract available


  430. FAHN S
    The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
    Mov Disord. 2014 Dec 9. doi: 10.1002/mds.26102.
    PubMed     Text format     Abstract available


  431. NABLI F, Ben Sassi S, Amouri R, Duda JE, et al
    Motor phenotype of LRRK2-associated Parkinson's disease: A tunisian longitudinal study.
    Mov Disord. 2014 Dec 9. doi: 10.1002/mds.26097.
    PubMed     Text format     Abstract available


  432. HAUSER RA, Isaacson S, Lisk JP, Hewitt LA, et al
    Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B).
    Mov Disord. 2014 Dec 9. doi: 10.1002/mds.26086.
    PubMed     Text format     Abstract available


  433. FAHN S, Poewe W
    Levodopa: 50 years of a revolutionary drug for Parkinson disease.
    Mov Disord. 2014 Dec 8. doi: 10.1002/mds.26122.
    PubMed     Text format    


  434. KAASINEN V, Vahlberg T, Suominen S
    Increasing age-adjusted male-to-female incidence ratio of Parkinson's disease.
    Mov Disord. 2014 Dec 5. doi: 10.1002/mds.26098.
    PubMed     Text format    


  435. SCHEPERJANS F, Aho V, Pereira PA, Koskinen K, et al
    Gut microbiota are related to Parkinson's disease and clinical phenotype.
    Mov Disord. 2014 Dec 5. doi: 10.1002/mds.26069.
    PubMed     Text format     Abstract available


  436. NAPIER TC, Corvol JC, Grace AA, Roitman JD, et al
    Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.
    Mov Disord. 2014 Dec 5. doi: 10.1002/mds.26068.
    PubMed     Text format     Abstract available


  437. GUSTAVSSON EK, Guella I, Trinh J, Szu-Tu C, et al
    Genetic variability of the retromer cargo recognition complex in parkinsonism.
    Mov Disord. 2014 Dec 5. doi: 10.1002/mds.26104.
    PubMed     Text format     Abstract available


  438. LEWITT PA
    Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
    Mov Disord. 2014 Dec 1. doi: 10.1002/mds.26082.
    PubMed     Text format     Abstract available


  439. PONT-SUNYER C, Hotter A, Gaig C, Seppi K, et al
    The Onset of Nonmotor Symptoms in Parkinson's disease (The ONSET PD Study).
    Mov Disord. 2014 Dec 1. doi: 10.1002/mds.26077.
    PubMed     Text format     Abstract available


  440. BROCKMANN K, Srulijes K, Pflederer S, Hauser AK, et al
    GBA-associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study.
    Mov Disord. 2014 Dec 1. doi: 10.1002/mds.26071.
    PubMed     Text format     Abstract available


  441. PINTER B, Diem-Zangerl A, Wenning GK, Scherfler C, et al
    Mortality in Parkinson's disease: A 38-year follow-up study.
    Mov Disord. 2014 Dec 1. doi: 10.1002/mds.26060.
    PubMed     Text format     Abstract available


  442. BOLITHO SJ, Grunstein RR, Naismith SL, Melehan K, et al
    Reply: unified techniques are needed to diagnose REM sleep behavior disorder.
    Mov Disord. 2014;29:1836.
    PubMed     Text format    


  443. FANTINI ML, Figorilli M, Ferri R
    Rapid eye movement atonia is not rapid eye movement sleep behavior disorder.
    Mov Disord. 2014;29:1835.
    PubMed     Text format    


    November 2014
  444. GUSTAVSSON EK, Trinh J, Guella I, Vilarino-Guell C, et al
    DNAJC13 genetic variants in parkinsonism.
    Mov Disord. 2014 Nov 12. doi: 10.1002/mds.26064.
    PubMed     Text format     Abstract available


  445. MULLER ML, Bohnen NI, Kotagal V, Scott PJ, et al
    Clinical markers for identifying cholinergic deficits in Parkinson's disease.
    Mov Disord. 2014 Nov 12. doi: 10.1002/mds.26061.
    PubMed     Text format     Abstract available


  446. MARTINEZ-MARTIN P, Reddy P, Katzenschlager R, Antonini A, et al
    EuroInf: A multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
    Mov Disord. 2014 Nov 10. doi: 10.1002/mds.26067.
    PubMed     Text format     Abstract available


  447. VAN STEENOVEN I, Aarsland D, Hurtig H, Chen-Plotkin A, et al
    Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson's disease.
    Mov Disord. 2014 Nov 7. doi: 10.1002/mds.26062.
    PubMed     Text format     Abstract available


  448. DUJARDIN K, Langlois C, Plomhause L, Carette AS, et al
    Apathy in untreated early-stage Parkinson disease: Relationship with other non-motor symptoms.
    Mov Disord. 2014 Nov 5. doi: 10.1002/mds.26058.
    PubMed     Text format     Abstract available


  449. WEINTRAUB D, David AS, Evans AH, Grant JE, et al
    Clinical spectrum of impulse control disorders in Parkinson's disease.
    Mov Disord. 2014 Nov 5. doi: 10.1002/mds.26016.
    PubMed     Text format     Abstract available



  450. Supplement: abstracts of the fourth asian and oceanian Parkinson's disease and movement disorders congress.
    Mov Disord. 2014;29 Suppl 2:S1-S105.
    PubMed     Text format    


    September 2014
  451. YAMAKADO H
    Advance in PD research explored a new field on ubiquitin biology.
    Mov Disord. 2014;29:1243.
    PubMed     Text format    


  452. MONTGOMERY E, He H
    The FM/AM world is shaping the future of deep brain stimulation.
    Mov Disord. 2014;29:1327.
    PubMed     Text format    


  453. CHIASSERINI D, Persichetti E, Paciotti S, Beccari T, et al
    Lysosomal enzymes in PD: further evidence is needed.
    Mov Disord. 2014;29:1329.
    PubMed     Text format    


  454. FASANO A, Lozano AM
    Reply: the FM/AM world is shaping the future of deep brain stimulation.
    Mov Disord. 2014;29:1327-8.
    PubMed     Text format    


  455. CHEN H, Huang X, Guo X, Peddada S, et al
    Individual and joint prevalence of three nonmotor symptoms of PD in the US general population.
    Mov Disord. 2014;29:1316-9.
    PubMed     Text format     Abstract available


    August 2014
  456. VISANJI NP, Marras C, Liu LW, Hazrati LN, et al
    Reply to: Gray et al.
    Mov Disord. 2014;29:1225-6.
    PubMed     Text format    


    July 2014
  457. KELLY LP, Carvey PM, Keshavarzian A, Shannon KM, et al
    Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease.
    Mov Disord. 2014;29:999-1009.
    PubMed     Text format     Abstract available


  458. VALENTINO F, Cosentino G, Brighina F, Pozzi NG, et al
    Transcranial direct current stimulation for treatment of freezing of gait: a cross-over study.
    Mov Disord. 2014;29:1064-9.
    PubMed     Text format     Abstract available


    April 2014
  459. AARSLAND D, Taylor JP, Weintraub D
    Psychiatric issues in cognitive impairment.
    Mov Disord. 2014;29:651-62.
    PubMed     Text format     Abstract available


  460. SARKAR SN, Papavassiliou E, Hackney DB, Alsop DC, et al
    Three-dimensional brain MRI for DBS patients within ultra-low radiofrequency power limits.
    Mov Disord. 2014;29:546-9.
    PubMed     Text format     Abstract available


  461. SANTIAGO JA, Potashkin JA
    A network approach to diagnostic biomarkers in progressive supranuclear palsy.
    Mov Disord. 2014;29:550-5.
    PubMed     Text format     Abstract available


    March 2014
  462. NISHIJIMA H, Suzuki S, Kon T, Funamizu Y, et al
    Morphologic changes of dendritic spines of striatal neurons in the levodopa-induced dyskinesia model.
    Mov Disord. 2014;29:336-43.
    PubMed     Text format     Abstract available


  463. IRANZO A, Gelpi E, Tolosa E, Molinuevo JL, et al
    Neuropathology of prodromal Lewy body disease.
    Mov Disord. 2014;29:410-5.
    PubMed     Text format     Abstract available


  464. YACOUBIAN TA, Standaert DG
    Reaping what you sow: Cross-seeding between aggregation-prone proteins in neurodegeneration.
    Mov Disord. 2014;29:306.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: